mechanism	uricosuric _ drugs , such as <e10> drug1 </e10> , sulfasalazine , and nizoral _ acid , may inhibit the metabolism of <e20> drug2 </e20> , resulting in increased serum levels of drug2 .
mechanism	corticosteroids : a study in rats has shown that <e10> drug1 </e10> reduced the plasma levels of <e20> drug1 </e20> .
mechanism	nonsteroidal _ anti - inflammatory _ drugs : the hepatic absorption of <e10> drug1 </e10> and its derivatives was decreased when coadministered with <e20> drug2 </e20> .
mechanism	lithium : <e12> drug1 </e12> may increase the clearance of <e22> drug2 </e22> .
mechanism	valproate : a 5 - mg oral dose of <e10> drug1 </e10> significantly increased the auc and cmax of <e20> drug2 </e20> by 29 % and 21 % , respectively .
mechanism	macrolide _ antibiotics ( e , g , <e10> drug1 </e10> , clarithromycin , rifampin , etc , ) may decrease the absorption of <e20> drug2 </e20> and may increase the serum concentrations of drug2 and thus the exposure of the patient to aers .
mechanism	agents that are cyp3a4 inhibitors ( e , g , , ketoconazole , <e10> drug1 </e10> , ritonavir , clarithromycin , nefazodone , nelfinavir , indinavir , saquinavir , telithromycin , troleandomycin , didanosine , indinavir , drug1 , troleandomycin , saquinavir , indinavir , drug1 ) may increase plasma levels of <e20> drug2 </e20> and therefore may require an increase in dose of drug2 to achieve the desired plasma level .
mechanism	<e10> drug1 </e10> has been shown to inhibit <e20> drug2 </e20> and chloroquine absorption and to increase drug2 and chloroquine serum concentrations .
mechanism	<e10> drug1 </e10> inhibited <e20> drug2 </e20> binding with an ec50 of $ 15 mg / kg ( approximately # mg of arava / kg of body weight ) .
mechanism	rifampin : following administration of # mg <e10> drug1 </e10> , plasma concentrations of <e20> drug2 </e20> increased by approximately 43 % and that of progestin decreased by approximately 17 % .
mechanism	however , in a single - dose study , <e10> drug1 </e10> was found to reduce the plasma concentrations of <e20> drug2 </e20> by approximately 40 % and the rate of drug2 metabolism by approximately 40 % .
mechanism	antacids or h _ 2 _ receptor _ antagonists ( eg , <e10> drug1 </e10> ) may enhance the absorption of <e20> drug2 </e20> .
mechanism	drug1 : <e10> drug1 </e10> was found to increase the half - life of <e20> drug2 </e20> and its metabolism in vitro by approximately 50 % .
mechanism	in two clinical studies , the concomitant administration of <e10> drug1 </e10> and <e20> drug2 </e20> resulted in an increase in drug2 serum auc values by 5 % to 40 % .
mechanism	<e10> drug1 </e10> increased the auc of <e20> drug2 </e20> by 62 % .
mechanism	trough plasma drug1 concentrations were higher when <e10> drug1 </e10> was administered with <e20> drug2 </e20> ( ic50 : # microm ) , but lower when drug1 was administered with ampicillin ( ic50 : # microm ) .
mechanism	however , the peak plasma concentrations of <e10> drug1 </e10> are approximately 10 - fold greater when coadministered with <e20> drug1 </e20> .
mechanism	rifampin : co - administration of <e10> drug1 </e10> with <e20> drug2 </e20> produced a 19 % increase in the auc of drug2 .
mechanism	when <e10> drug1 </e10> was administered to healthy volunteers , the maximum plasma levels of <e20> drug2 </e20> were approximately two - to threefold higher than the levels achieved with drug1 alone .
mechanism	concomitant administration of <e10> drug1 </e10> tablets with <e20> drug2 </e20> tablets decreased the drug2 auc by 50 % and increased the drug2 auc by 67 % .
mechanism	we propose these results to suggest that <e12> drug1 </e12> may inhibit <e20> drug2 </e20> metabolism and result in an increase in drug2 clearance , thereby resulting in a decrease in the therapeutic index of drug2 .
mechanism	<e11> drug1 </e11> can reduce the clearance of <e20> drug2 </e20> by 46 % .
mechanism	<e11> drug1 </e11> has been shown to increase the bioavailability of <e20> drug2 </e20> .
mechanism	products containing calcium and <e10> drug1 </e10> may inhibit the absorption of <e20> drug2 </e20> .
mechanism	acidifying _ agents : gastrointestinal _ acidifying _ agents ( e , g , , <e10> drug1 </e10> , nalidixic _ acid ) or h2 - receptor - antagonists ( e , g , , phenobarbital , phenytoin , triazolam ) may cause a decrease in <e20> drug2 </e20> plasma concentrations .
mechanism	however , co administration of <e10> drug1 </e10> and <e20> drug2 </e20> results in a 3 - fold increase in drug2 cmax .
mechanism	drug1 : <e10> drug1 </e10> may reduce the absorption of <e20> drug2 </e20> and other anticholinergics , increase the blood levels of norethindrone , and increase the metabolism of some amphetamines , especially after administration of a single dose of a potent , single - dose , intravenous , cimetidine - type amphetamine .
mechanism	the absorption of <e11> drug1 </e11> is decreased by the metabolism of <e20> drug2 </e20> and the concomitant use of a cyclosporine _ inhibitor or cyclosporine ( previously known as enalapril ) with drug1 .
mechanism	<e10> drug1 </e10> may decrease the bioavailability of <e20> drug2 </e20> .
mechanism	drug1 : <e10> drug1 </e10> has been shown to decrease the clearance of <e20> drug2 </e20> .
mechanism	the plasma concentration of <e10> drug1 </e10> is increased by the following : # mg / day of <e20> drug2 </e20> and # mg / day of ritonavir .
mechanism	co - administration with <e10> drug1 </e10> ( 200 mg / day ) increased the hepatic clearance of <e20> drug2 </e20> by approx . 35 % ( p < # ) and reduced the clearance of drug1 by approx . 50 % ( p < # ) at the high dose of # mg / day .
mechanism	<e10> drug1 </e10> may enhance the metabolism of <e20> drug2 </e20> .
mechanism	agents that are strong inhibitors of cyp3a4 ( eg , ketoconazole , itraconazole , erythromycin , clarithromycin , nefazodone , troleandomycin , <e10> drug1 </e10> , nelfinavir ) may increase the plasma concentrations of <e20> drug2 </e20> and may not be effective if the drug2 level is high .
mechanism	erythromycin : in a clinical study in healthy volunteers , the auc of <e10> drug1 </e10> increased by 53 % when it was coadministered with <e20> drug2 </e20> .
mechanism	drug1 : ketoprofen - <e10> drug1 </e10> ( 40 mg , qid ) increased <e20> drug2 </e20> concentrations by 15 % and approximately 50 % .
mechanism	uricosuric _ drugs , such as <e10> drug1 </e10> , phenobarbital , carbamazepine , and others , reduce the renal clearance of <e20> drug2 </e20> , resulting in a greater accumulation in the urine of the latter .
mechanism	in vitro studies have demonstrated that <e10> drug1 </e10> increases the absorption of <e20> drug2 </e20> .
mechanism	after multiple dosing , <e10> drug1 </e10> decreased the auc of <e20> drug2 </e20> by 48 % and the cmax by 46 % , and the auc and cmax of drug1 were reduced by 56 % and 25 % , respectively , compared with drug2 alone .
mechanism	concomitant administration of <e10> drug1 </e10> and <e20> drug2 </e20> , an inhibitor of cyp3a4 , decreased the exposure of drug1 by approximately 50 % and decreased the half - life by approximately 50 % .
mechanism	oral doses of <e10> drug1 </e10> # mg bid and # mg cid significantly increased the cmax and auc of <e20> drug2 </e20> .
mechanism	dicumarol : it has been reported that <e10> drug1 </e10> decreased the clearance of <e20> drug2 </e20> and cimetidine .
mechanism	binding to serum albumin or plasma proteins : antacids ( e , g , , vitamin _ b - 12 , <e10> drug1 </e10> ) are known to decrease the binding of <e20> drug2 </e20> to serum albumin or plasma proteins , and antacids containing calcium ( e , g , , calcium supplements or folic acid ) , magnesium ( e , g , , magnesium supplements or folic acid ) , or zinc ( e , g , , zinc supplements or folic acid ) increase the binding of drug2 to serum albumin or plasma proteins .
mechanism	allopurinol : the co - administration of <e10> drug1 </e10> with <e20> drug2 </e20> at clinically effective doses resulted in a 19 % increase in drug2 clearance and a decrease in drug2 auc from # + / - 7 to # + / - 5 mg / h .
mechanism	hepatic enzyme inducers , including aminoglycosides , tetracyclines , sulfonamides , sulfonamides , chloramphenicol , and <e10> drug1 </e10> , may increase <e20> drug2 </e20> concentrations and result in elevated serum drug2 concentrations .
mechanism	there is a strong trend in these studies to see a decrease in the clearance of <e10> drug1 </e10> when co - administered with <e20> drug2 </e20> and / or a metabolite of drug2 , but there are no reports on the effect of drug1 on serum concentrations of drug2 and its metabolite .
mechanism	on the basis of these results , it is expected that <e10> drug1 </e10> may have an effect on blood levels of <e20> drug2 </e20> and other anticonvulsants , and conversely , that its effect on blood levels of concomitant anticonvulsants may be increased .
mechanism	<e10> drug1 </e10> decreased the metabolism of <e20> drug2 </e20> and significantly increased plasma levels of citalopram .
mechanism	increases in plasma concentrations of <e10> drug1 </e10> have been observed when <e20> drug2 </e20> has been coadministered .
mechanism	acidifying _ agents : gastrointestinal _ acidifying _ agents ( eg , <e10> drug1 </e10> ) may interfere with the metabolism of <e20> drug2 </e20> , resulting in a decrease in serum concentrations of the latter .
mechanism	anticonvulsants ( drug2 , phenobarbital , phenytoin , felbamate ) : <e10> drug1 </e10> may inhibit the metabolism of <e20> drug2 </e20> , phenobarbital , and phenytoin , resulting in elevated plasma concentrations of these drugs .
mechanism	cyclosporine , digoxin , methotrexate , and <e10> drug1 </e10> reduce the renal clearance of <e20> drug2 </e20> .
mechanism	warfarin , digoxin , and phenytoin : <e10> drug1 </e10> potentiates the gastrointestinal absorption of <e20> drug2 </e20> , digoxin , and phenytoin , thus increasing the risk of gastrointestinal toxicity .
mechanism	<e10> drug1 </e10> reduced the plasma levels of <e20> drug2 </e20> by 50 % but did not significantly affect the plasma levels of either the hydrochlorothiazide or levodopa .
mechanism	the following are noted : ( 1 ) in vitro , <e10> drug1 </e10> inhibited <e20> drug2 </e20> metabolism , resulting in a decrease in drug2 concentrations .
mechanism	<e12> drug1 </e12> or other digestive products may reduce the absorption of <e20> drug2 </e20> , a cationic metallo - beta - lactamase inhibitor .
mechanism	ketoconazole : coadministration of <e11> drug1 </e11> with <e20> drug2 </e20> reduced its maximum plasma concentration by two - fold .
mechanism	benzodiazepines : combination <e10> drug1 </e10> may inhibit the metabolism of benzodiazepines such as alprazolam , <e20> drug2 </e20> , triazolam , and alprazolam , resulting in elevated plasma concentrations of these drugs .
mechanism	drugs which induce hepatic metabolism of <e11> drug1 </e11> include : alcohol , nonsteroidal _ anti - inflammatory _ drugs , <e20> drug2 </e20> , disulfiram , sulfasalazine , tricyclic _ antidepressants , methadone , theophylline , warfarin , and nonsteroidal _ anti - inflammatory _ drugs .
mechanism	the gastrointestinal absorption of <e10> drug1 </e10> may be increased by coadministration with <e20> drug2 </e20> , resulting in decreased plasma levels of drug1 .
mechanism	drug1 : <e10> drug1 </e10> may reduce plasma <e20> drug2 </e20> concentrations .
mechanism	h2 - receptor _ antagonists : co - administration of <e10> drug1 </e10> with <e20> drug2 </e20> increases drug2 serum concentrations by approximately 50 % .
mechanism	co - medications that induce cyp3a4 activity , including ketoconazole , itraconazole , erythromycin , felbamate , cisapride , <e10> drug1 </e10> , cimetidine , omeprazole , ketoconazole , valdecoxib , fluoxetine , ketoconazole and sulfasalazine , may increase plasma concentrations of <e20> drug2 </e20> .
mechanism	<e10> drug1 </e10> increases the clearance of <e20> drug2 </e20> , which is used to treat metastatic breast cancer .
mechanism	antacids or h _ 2 _ receptor _ antagonists such as phenytoin , tacrolimus , or <e10> drug1 </e10> may inhibit the absorption of <e20> drug2 </e20> or , in some patients , cause a marked increase in the plasma levels of drug2 .
mechanism	when <e10> drug1 </e10> was added to the daily regimen of two women who were receiving <e20> drug2 </e20> , the two combined - dose oral plasma concentrations of drug1 were significantly higher than when drug2 was administered alone .
mechanism	furthermore , rifampin , clofibrate , and <e10> drug1 </e10> may enhance the metabolism of the <e22> drug2 </e22> , resulting in an increased elimination of the rifampin , clofibrate , and drug1 .
mechanism	selegiline : <e12> drug1 </e12> may interfere with the absorption of <e20> drug2 </e20> .
mechanism	increasing the <e10> drug1 </e10> dose to # mg / day increased the serum <e20> drug2 </e20> level by 50 % and resulted in a 20 % increase in the drug1 - stimulated serum t3 level in healthy volunteers .
mechanism	binding to serum : - <e10> drug1 </e10> has been reported to interfere with absorption of <e20> drug2 </e20> in some patients .
mechanism	results of preliminary studies of patients receiving <e10> drug1 </e10> , nevirapine , or other hiv drugs concurrently with <e20> drug2 </e20> indicate an increase in cmax and auc .
mechanism	the absorption of <e10> drug1 </e10> is enhanced by co - administration of <e20> drug2 </e20> and / or azithromycin .
mechanism	some <e12> drug1 </e12> have been reported to decrease the clearance of digoxin and <e20> drug2 </e20> , resulting in a concomitant rise in blood levels .
mechanism	oral doses of <e10> drug1 </e10> # mg and # mg for # days each week were associated with a reduction of <e20> drug2 </e20> auc by 10 % and 40 % , respectively .
mechanism	drug1 : <e10> drug1 </e10> significantly inhibits <e20> drug2 </e20> metabolism , resulting in lower plasma levels of drug2 and higher aucs of drug2 .
mechanism	presumably , <e10> drug1 </e10> may interfere with metabolism of <e20> drug2 </e20> .
mechanism	antacids and sucralfate : <e10> drug1 </e10> , aluminum , and iron containing antacids may inhibit the absorption of <e20> drug2 </e20> .
mechanism	administration of <e10> drug1 </e10> at doses of # mg / day to male rats , produced an approximately 3 - fold increase in <e20> drug1 </e20> metabolism compared to the control group .
mechanism	while no in vitro studies have been conducted , it is likely that the action of <e10> drug1 </e10> may be increased by concomitant use of other <e22> drug2 </e22> .
mechanism	enhanced <e10> drug1 </e10> elimination by about 50 % during dosing with <e20> drug2 </e20> # mg once daily .
mechanism	drug1 or cimetidine : in a study in healthy volunteers , <e10> drug1 </e10> or cimetidine significantly decreased the plasma concentrations of <e20> drug2 </e20> by approximately 34 % .
mechanism	<e10> drug1 </e10> reduced the clearance of <e20> drug2 </e20> by 17 % ( p = 0 . 0001 ) .
mechanism	treatment with <e11> drug1 </e11> ( 3 mg q # h ) resulted in a significant increase in plasma <e20> drug2 </e20> concentrations of # % to # mg / l and decreased serum drug2 levels by approximately # % to # mg / l ( p = . 02 and p = . 002 , respectively ) .
mechanism	when used in a dose of # mg / kg , <e10> drug1 </e10> increased the <e20> drug2 </e20> and haloperidol serum concentrations by 26 % and 18 % , respectively .
mechanism	a # to # mg dose of <e10> drug1 </e10> may decrease the plasma concentrations of <e20> drug2 </e20> by 20 % to 40 % .
mechanism	serum concentration of <e10> drug1 </e10> may be reduced by <e20> drug2 </e20> , which is metabolized by cytochrome p450 3a4 ( cyp3a4 ) , and by aripiprazole , which has a cyp3a4 inhibitory effect .
mechanism	studies showed that <e10> drug1 </e10> enhanced <e20> drug2 </e20> metabolism , which may be related to vitamin k inhibition of vitamin k1 activity .
mechanism	concomitant single dose administration of <e10> drug1 </e10> ( 4 mg / kg ) and <e20> drug2 </e20> ( 20 mg / kg ) significantly increased the drug1 plasma concentration by approximately 5 % .
mechanism	drug1 : <e10> drug1 </e10> significantly increased plasma concentrations of <e20> drug2 </e20> by 5 - fold and plasma concentrations of estrogen by 2 - fold .
mechanism	<e10> drug1 </e10> in plasma significantly increased <e20> drug2 </e20> ( 95 % of drug2 plasma concentrations were above # microm ) and its r ( + ) isomer , drug2 cis - 3 - c , aproximately .
mechanism	methotrexate : <e10> drug1 </e10> can inhibit the metabolism of <e20> drug2 </e20> .
mechanism	in vitro studies have shown that <e10> drug1 </e10> increased the clearance of <e20> drug2 </e20> by approximately 3 - fold , whereas the elimination of drug2 was unaffected by drug1 .
mechanism	antacids and sucralfate : <e10> drug1 </e10> and sucralfate decrease absorption of <e20> drug2 </e20> and phenobarbital .
mechanism	<e10> drug1 </e10> and bromocriptine _ mesylate ( e , g , , drug1 ) enhance <e20> drug2 </e20> metabolism and produce a 5 - fold increase in auc and cmax .
mechanism	in a study in healthy volunteers , the effect of oral <e10> drug1 </e10> was reduced by approximately two - fold and increased by approximately tenfold by concomitant administration of <e20> drug2 </e20> , a known aminoglycoside metabolite .
mechanism	barbiturates , phenytoin , and <e10> drug1 </e10> may increase the clearance of <e20> drug2 </e20> .
mechanism	studies showed that <e10> drug1 </e10> reduced the half - life of <e20> drug2 </e20> by 50 % .
mechanism	prednisolone : <e10> drug1 </e10> significantly increased the <e20> drug2 </e20> auc by 23 % ( p = 0 . 009 ) .
mechanism	however , the peak plasma concentrations of <e10> drug1 </e10> are increased by approximately 50 % when <e20> drug2 </e20> is coadministered .
mechanism	discussion : <e10> drug1 </e10> may have the potential to interfere with the metabolism of <e20> drug2 </e20> .
mechanism	<e10> drug1 </e10> at a dose of # mg / day for # days may increase the plasma concentrations of <e20> drug2 </e20> by 20 % .
mechanism	in vitro studies have shown that <e10> drug1 </e10> ( 200 mg twice daily ) reduced the plasma concentrations of <e20> drug2 </e20> by about 50 % and the half - life was lengthened by approximately 20 % .
mechanism	absorption of <e10> drug1 </e10> is impaired when <e20> drug2 </e20> is coadministered .
mechanism	inhibitors of cyp3a4 ( e , g , , ketoconazole , erythromycin , ritonavir , erythromycin , clarithromycin , <e10> drug1 </e10> , itraconazole , nefazodone , troleandomycin ) increase the clearance of <e20> drug2 </e20> , resulting in increased blood levels .
mechanism	coadministration of <e10> drug1 </e10> with <e20> drug2 </e20> , a potent inhibitor of cyp3a4 activity , resulted in a 15 % increase in drug2 auc ( p = . 0016 ) .
mechanism	<e10> drug1 </e10> may decrease the renal clearance of ketoconazole and other <e22> drug2 </e22> .
mechanism	reports in the literature suggest that <e10> drug1 </e10> can inhibit the metabolism of ketoconazole and other strong cyp3a4 inhibitors ( <e20> drug2 </e20> , fluoxetine , paroxetine , and alfentanil ) and inhibitory effects of drug1 can be potentiated by high concentrations of these drugs .
mechanism	drug1 : <e10> drug1 </e10> may increase the metabolism of <e20> drug2 </e20> .
mechanism	<e10> drug1 </e10> reduces <e20> drug2 </e20> serum concentrations by lowering the rate of platelet inhibition by drug2 .
mechanism	dexamethasone : steady - state plasma concentrations of <e10> drug1 </e10> were decreased by 62 % when <e20> drug2 </e20> was coadministered .
mechanism	<e13> drug1 </e13> may inhibit the metabolism of <e20> drug2 </e20> .
mechanism	protease _ inhibitors : amprenavir , <e10> drug1 </e10> , indinavir , saquinavir , indinavir , drug2 , and clarithromycin may reduce plasma levels of <e20> drug2 </e20> .
mechanism	agents that are cyp3a4 inhibitors ( e , g , , ketoconazole , <e10> drug1 </e10> , ritonavir , indinavir , saquinavir , nelfinavir ) decrease plasma levels of <e20> drug2 </e20> .
mechanism	agents that are predominantly metabolized by cytochrome p450 3a4 ( cyp3a4 ) ( eg , diltiazem , <e10> drug1 </e10> , clarithromycin ) may reduce the metabolism of <e20> drug2 </e20> .
mechanism	<e10> drug1 </e10> markedly inhibited <e20> drug2 </e20> metabolism , resulting in a 3 - to 5 - fold increase in auc and cmax .
mechanism	however , # mg <e10> drug1 </e10> tablets increased <e20> drug2 </e20> auc from # to # ng / ml .
mechanism	in vitro studies have shown that <e10> drug1 </e10> causes a dose - dependent decrease in the clearance of <e20> drug2 </e20> .
mechanism	the plasma concentration of <e10> drug1 </e10> is reduced by approximately 40 % in patients receiving <e20> drug2 </e20> .
mechanism	drug1 : <e10> drug1 </e10> may decrease the clearance of <e20> drug2 </e20> .
mechanism	multivalent cation - containing products : <e10> drug1 </e10> ( erythromycin ) may increase the exposure of <e20> drug2 </e20> .
mechanism	intestinal _ adsorbents ( e , g , , <e10> drug1 </e10> , ciprofloxacin , gentamicin , erythromycin , clarithromycin , dalfopristin , fluconazole , indomethacin , itraconazole , itraconazole sulfone ) inhibit the absorption of <e20> drug2 </e20> .
mechanism	drug1 : <e10> drug1 </e10> significantly increased the half - life of <e20> drug2 </e20> .
mechanism	in vitro data suggest that <e10> drug1 </e10> may have an additive effect on <e20> drug2 </e20> absorption and that absorption may be enhanced by combination therapy with either ketoconazole or cimetidine .
mechanism	agents that are cyp 3a4 inhibitors ( e , g , , ketoconazole , drug2 , clarithromycin , ritonavir , indinavir , <e10> drug1 </e10> , nefazodone , nelfinavir , saquinavir , telithromycin ) may increase plasma concentrations of <e20> drug2 </e20> .
mechanism	a number of <e12> drug1 </e12> have been shown to reduce the metabolism of <e20> drug2 </e20> , and the effect on the auc of drug2 may be clinically significant .
mechanism	drug1 : <e10> drug1 </e10> inhibits the absorption of <e20> drug2 </e20> , thus lowering the systemic exposure of drug2 .
mechanism	acetaminophen : in vitro data indicate that <e10> drug1 </e10> inhibits the metabolism of <e20> drug2 </e20> by inducing a two - fold decrease in the steady - state plasma concentrations of ( i ) the phenolic metabolites of drug2 ( phenylbutazone , phenylacetylsalicylate , and salicylate ) and ( ii ) the oxidized products of phenylbutazone and salicylate .
mechanism	corticosteroids : dexamethasone ( <e10> drug1 </e10> ) and retinyl _ acetate ( retinyl _ acetate ) inhibit <e20> drug2 </e20> in vitro and in vivo , leading to an increase in auc values .
mechanism	drug1 : <e10> drug1 </e10> , like other drugs , can decrease the absorption of <e20> drug2 </e20> , and therefore , the effective dose of the parent drug .
mechanism	withdrawal of <e10> drug1 </e10> ( 100 mg ) increased <e20> drug2 </e20> s half - life by approximately 50 % ( from 4 to 6 hours ) , and the half - life of cisapride was increased by approximately 25 % .
mechanism	phenytoin / phenobarbital : <e10> drug1 </e10> may decrease the renal clearance of <e20> drug2 </e20> and may increase the renal clearance of phenytoin and drug2 .
mechanism	propantheline and <e10> drug1 </e10> may interfere with the metabolism of <e20> drug2 </e20> , leading to decreased blood levels .
mechanism	coadministration of oral <e10> drug1 </e10> with a <e22> drug2 </e22> increased the auc of drug1 by approximately 20 % .
mechanism	phenytoin : <e12> drug1 </e12> , like other stimulants , may increase the absorption of <e20> drug2 </e20> .
mechanism	antifungals : in vitro studies with two azole _ antifungals ( <e10> drug1 </e10> and ketoconazole ) , which are potent inhibitors of azole metabolism , indicate that their clearance is impaired by <e20> drug2 </e20> , an inhibitor of hepatic metabolism .
mechanism	the absorption of <e10> drug1 </e10> may be enhanced by concomitant administration of <e20> drug2 </e20> .
mechanism	drug1 : <e10> drug1 </e10> reduced the clearance of <e20> drug2 </e20> by 25 % .
mechanism	pretreatment of healthy volunteers with <e10> drug1 </e10> decreased the plasma levels of <e20> drug2 </e20> by approximately 50 % and increased the plasma levels of 17beta - drug2 by approximately 20 % .
mechanism	cimetidine - in vitro data from patients with chronic renal insufficiency have shown that <e10> drug1 </e10> , when given with <e20> drug2 </e20> , increases the mic of drug1 by up to # times .
mechanism	<e10> drug1 </e10> decreased plasma levels of <e20> drug2 </e20> by 35 % .
mechanism	however , the systemic administration of <e10> drug1 </e10> at # mg / kg , twice daily for # days has been associated with a 2 - fold increase in <e20> drug1 </e20> auc .
mechanism	however , the systemic exposure of <e10> drug1 </e10> in patients on cyclosporine a , tacrolimus , or <e20> drug2 </e20> may be increased , resulting in decreased antitumour activity of drug1 .
mechanism	even so <e10> drug1 </e10> increased the <e20> drug1 </e20> plasma half - life ( 6 to 7 days ) and decreased the half - life of the oral drug ( approximately 7 days ) .
mechanism	cholestyramine - concomitant intake of <e10> drug1 </e10> with <e20> drug2 </e20> decreased the clearance of drug2 by approximately 7 % .
mechanism	in addition , other drugs that are potent inhibitors of cyp3a4 activity ( eg , fluconazole , ketoconazole , <e10> drug1 </e10> , rifampin , nefazodone , troleandomycin , clarithromycin , clarithromycin , erythromycin , terfenadine , bromocriptine , bromocriptine , valdecoxib ) have been reported to decrease the extent of <e20> drug2 </e20> plasma exposure .
mechanism	single doses of <e11> drug1 </e11> significantly decreased the cmax and auc of <e20> drug2 </e20> .
mechanism	plasma levels of <e10> drug1 </e10> were decreased by 53 % following coadministration with <e20> drug2 </e20> .
mechanism	in a multiple - dose study in healthy volunteers , a single dose of # mg <e10> drug1 </e10> produced a mean reduction in <e20> drug2 </e20> clearance of 19 % compared to placebo .
mechanism	colestipol : plasma concentrations of <e10> drug1 </e10> were approximately # % higher when administered concurrently with <e20> drug2 </e20> .
mechanism	<e10> drug1 </e10> decreased the clearance of <e20> drug2 </e20> by approximately 50 % .
mechanism	short - term pharmacokinetic studies indicate that <e10> drug1 </e10> # mg taken once daily decreased mean plasma exposure of <e20> drug2 </e20> to # % .
mechanism	methotrexate : <e10> drug1 </e10> may decrease <e20> drug2 </e20> exposure .
mechanism	effects of other drugs and substances pertuzide : <e10> drug1 </e10> may interfere with <e20> drug2 </e20> metabolism and decrease the effectiveness of both the parent drug and a metabolite .
mechanism	<e10> drug1 </e10> has been shown to increase the clearance of a <e20> drug2 </e20> .
mechanism	<e10> drug1 </e10> may enhance the absorption of <e20> drug2 </e20> , but this should be noted in those patients treated with other antacids , sucralfate , or other medications that interfere with stomach acid secretion .
mechanism	the plasma concentration of <e10> drug1 </e10> was decreased by approximately 38 % when it was given concurrently with <e20> drug2 </e20> .
mechanism	agents that are vasoconstrictive ( eg , <e10> drug1 </e10> , indomethacin ) may increase the plasma levels of <e20> drug2 </e20> .
mechanism	<e10> drug1 </e10> may decrease <e20> drug2 </e20> clearance .
mechanism	<e11> drug1 </e11> may decrease the clearance of <e20> drug2 </e20> and other diuretics , causing a decrease in blood pressure .
mechanism	verapamil : coadministration of <e10> drug1 </e10> # mg and <e20> drug2 </e20> # mg decreased the area under the curve of drug2 by 25 % to 40 % .
mechanism	co - treatment with the protease inhibitor <e10> drug1 </e10> ( 5 mg q24h ) decreased the plasma level of <e20> drug2 </e20> by 40 % .
mechanism	drugs that cause an increase in plasma concentrations of <e11> drug1 </e11> include certain antihistamines ( tricyclic _ antidepressants , amitriptyline , nortriptyline , <e20> drug2 </e20> , nisoldipine ) , certain antihistamines ( bromocriptine ) , some anticonvulsants ( carbamazepine , felbamate , phenobarbital , phenytoin , primidone , triazolam ) , some tricyclic _ antidepressants ( amitriptyline , nortriptyline , alprazolam ) , some phenothiazines ( alprazolam , oxazolam ) , and certain other psychotropic _ agents ( theophylline , carbamazepine , alfentanil , fluoxetine , sertraline , alprazolam , bromocriptine , phenoth
mechanism	ingestion of <e10> drug1 </e10> # mg decreased plasma <e20> drug2 </e20> levels by 15 % , whereas no such effect was observed with # mg of bromocriptine _ mesylate .
mechanism	digoxin : some <e12> drug1 </e12> may increase serum levels of <e20> drug2 </e20> .
mechanism	multivalent cation - containing products : <e10> drug1 </e10> is known to have a significant effect on the pharmacokinetics of a number of multivalent cation - containing products , such as the following : <e20> drug2 </e20> and other nonsteroidal _ anti - inflammatory _ drugs , salicylates , some bile salts , some corticosteroids , and bromocriptine .
mechanism	anticonvulsants ( carbamazepine , phenobarbital , phenytoin , primidone ) : <e10> drug1 </e10> may increase the metabolism of <e20> drug2 </e20> , which may decrease drug2 serum levels .
mechanism	cyclosporine : elevated plasma concentrations of <e10> drug1 </e10> may interfere with clearance of <e20> drug2 </e20> .
mechanism	colchicine para - aminosalicylic _ acid and / or <e10> drug1 </e10> may interfere with absorption of <e20> drug2 </e20> , resulting in lower serum levels .
mechanism	<e10> drug1 </e10> decreases the metabolism of <e20> drug2 </e20> and increases the clearance of intravenous inotropes such as cetirizine , triazolam , and cisapride .
mechanism	the plasma concentration of <e10> drug1 </e10> increased by 38 % when it was given concomitantly with <e20> drug2 </e20> .
mechanism	separating the doses of <e10> drug1 </e10> and <e20> drug2 </e20> at # to # mg / kg for # days in male and female rats , respectively , decreased the drug2 auc by approximately 20 % to 30 % .
mechanism	carbamazepine : coadministration of <e10> drug1 </e10> and <e20> drug2 </e20> increased auc of drug2 by about 50 % .
mechanism	probenecid : concomitant administration of <e10> drug1 </e10> with <e20> drug2 </e20> significantly increased its auc and cmax .
mechanism	although specific studies have not been conducted , <e10> drug1 </e10> may increase the bioavailability of some oral <e22> drug2 </e22> .
mechanism	<e10> drug1 </e10> has been reported to increase the plasma levels of <e20> drug2 </e20> .
mechanism	<e11> drug1 </e11> may increase the clearance of both <e20> drug2 </e20> and a dicumarol - type steroidal metabolite , with the latter generally being a stronger inhibitor of cyp3a4 activity than drug2 .
mechanism	plasma concentrations of <e10> drug1 </e10> are reduced by the following : phenytoin , digoxin , sulfinpyrazone , cholestyramine , and rifampin , as well as <e20> drug2 </e20> .
mechanism	agents that are cyp3a4 inhibitors , including <e10> drug1 </e10> , clarithromycin , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , troleandomycin , and drug1 , inhibit <e20> drug2 </e20> metabolism by inhibiting cyp3a4 .
mechanism	phenytoin / phenobarbital : decreased plasma concentrations of <e10> drug1 </e10> have been reported when <e20> drug2 </e20> is administered concurrently .
mechanism	- drugs that induce hepatic enzymes ( eg , <e10> drug1 </e10> , carbamazepine , cholestyramine , lovastatin ) may decrease the clearance of <e20> drug2 </e20> .
mechanism	phenytoin : population pharmacokinetics ( pk ) studies suggest that <e10> drug1 </e10> may reduce the clearance of <e20> drug2 </e20> .
mechanism	<e10> drug1 </e10> - containing preparations may interfere with absorption of <e20> drug2 </e20> - containing preparations .
mechanism	allopurinol : the pharmacokinetics of <e10> drug1 </e10> is increased by <e20> drug2 </e20> , likely because of increased absorption resulting in lower levels of drug1 and , possibly , increased serum drug2 levels .
mechanism	drug1 : <e10> drug1 </e10> markedly inhibits the in vitro metabolism of <e20> drug2 </e20> and other glucocorticoids .
mechanism	studies showed that <e10> drug1 </e10> inhibited the absorption of both <e20> drug2 </e20> and cyclosporine , which resulted in high blood levels of drug2 .
mechanism	although the mechanism is not known , <e10> drug1 </e10> may interfere with the absorption of <e20> drug2 </e20> or other nonsteroidal _ anti - inflammatory _ drugs , causing lower levels to be released .
mechanism	previous studies have shown that <e10> drug1 </e10> increases the clearance of other <e22> drug2 </e22> and that their elimination may be enhanced by concomitant administration of other agents that decrease the plasma levels of the target enzyme , such as ketoconazole , itraconazole , ritonavir , indinavir , saquinavir , telithromycin , troleandomycin .
mechanism	cyclosporine : administration of <e10> drug1 </e10> decreased the clearance of <e20> drug2 </e20> , and an increase in drug2 concentrations occurred when drug1 was given concurrently with the study drugs .
mechanism	agents that are active in inhibiting cyp3a4 activity , such as <e10> drug1 </e10> , fluconazole , itraconazole , phenytoin , ritonavir , indinavir , saquinavir , indinavir _ c , and troleandomycin have been reported to reduce the half - life of <e20> drug2 </e20> by 20 % to 50 % .
mechanism	<e11> drug1 </e11> may also reduce the hepatic metabolism of <e20> drug2 </e20> and amphetamines , potentially resulting in increased auc and cmax .
mechanism	furthermore , rifampin , phenytoin , and <e10> drug1 </e10> may interfere with the metabolism of <e20> drug2 </e20> , resulting in lower plasma concentrations and increased toxicity .
mechanism	drug1 theobromine grepafloxacin tablets drug1 - <e10> drug1 </e10> inhibits the metabolism of <e20> drug2 </e20> and therefore should be used with caution in patients on chronic renal dialysis .
mechanism	the steady state plasma concentration of <e10> drug1 </e10> decreased by 20 % when <e20> drug2 </e20> was coadministered .
mechanism	inhibitors of cyp3a4 ( such as ketoconazole , itraconazole , erythromycin , clarithromycin , ritonavir , <e10> drug1 </e10> , nelfinavir , saquinavir , indinavir , saquinavir , erythromycin , troleandomycin , didanosine , troleandomycin , zidovudine ) have been reported to decrease plasma levels of <e20> drug2 </e20> .
mechanism	although specific studies have not been conducted , <e10> drug1 </e10> , as well as other drugs , may decrease the clearance of certain corticosteroids and certain nonsteroidal _ anti - inflammatory _ drugs , and increase the clearance of the oral anticoagulant <e20> drug2 </e20> .
mechanism	protease _ inhibitors : in clinical studies , <e10> drug1 </e10> has been reported to decrease plasma concentrations of <e20> drug2 </e20> , its active metabolite .
mechanism	drug1 : <e10> drug1 </e10> decreases the elimination of <e20> drug2 </e20> by 50 % .
mechanism	when used in combination with other anticholinesterase _ agents , <e10> drug1 </e10> ( diazol ) has the potential to decrease plasma concentrations of <e20> drug2 </e20> .
mechanism	therefore , <e10> drug1 </e10> may decrease the metabolism of <e20> drug2 </e20> .
mechanism	<e10> drug1 </e10> can inhibit the metabolism of <e20> drug2 </e20> , causing a higher absorption of the drug .
mechanism	alprazolam : when administered concomitantly with <e10> drug1 </e10> , the following drugs ( including acetaminophen , tylenol , phenobarbital , dilantin , phenytoin , and <e20> drug2 </e20> ) may result in a significantly increased absorption of drug1 : cimetidine , phenobarbital , dilantin , phenytoin , and st . john ' s wort .
mechanism	in clinical trials , <e10> drug1 </e10> caused a 25 % increase in <e20> drug2 </e20> clearance and a 22 % increase in drug2 blood levels .
mechanism	in vitro studies indicate that the <e12> drug1 </e12> produce inhibitory effects on the metabolism of <e20> drug2 </e20> , which is an active metabolite of a single dose of drug2 .
mechanism	methenamine therapy : urinary excretion of <e10> drug1 </e10> may be increased by approximately # % when <e20> drug2 </e20> is given concurrently .
mechanism	anticonvulsants ( carbamazepine , felbamate , phenobarbital , phenytoin , <e10> drug1 </e10> ) : effects on <e20> drug2 </e20> metabolism are likely to be acute .
mechanism	therefore , <e10> drug1 </e10> has been reported to increase plasma concentrations of <e20> drug2 </e20> and dipyridamole by several times .
mechanism	the following are among the drugs which may increase the plasma concentrations of <e10> drug1 </e10> and decrease the plasma concentrations of <e20> drug1 </e20> are : the anticonvulsant carbamazepine , phenytoin , phenobarbital , the phenytoin metabolized to carbamazepine ( e , g , , carbamazepine sulfate ) , the phenytoin metabolized to ketoconazole ( e , g , , ketoconazole ) , the anticonvulsant carbamazepine , the anticonvulsant cyclosporine , the anticonvulsant diltiazem , the anticonvulsant flecainide , the anticonvulsant rifampin , the anticonvulsant sulfasalazine , the anticonvulsant tetracycline , the anticonvulsant methotrexate , the anticonv
mechanism	caffeine drug1 <e10> drug1 </e10> can inhibit <e20> drug2 </e20> absorption .
mechanism	levothyroxine _ sodium absorption : the absorption of <e11> drug1 </e11> is significantly reduced when it is administered with <e20> drug2 </e20> .
mechanism	protease _ inhibitors : amprenavir , ritonavir , indinavir , <e10> drug1 </e10> , and itraconazole have been reported to decrease plasma concentrations of <e20> drug2 </e20> .
mechanism	quinidine , verapamil , and <e10> drug1 </e10> reduce the clearance of <e20> drug2 </e20> .
mechanism	- drug1 : <e10> drug1 </e10> has been reported to decrease the renal clearance of <e20> drug2 </e20> and to increase the clearance of cisapride .
mechanism	inhibitors of cyp3a4 ( eg , ketoconazole , itraconazole , erythromycin , drug2 , nefazodone , <e10> drug1 </e10> , ritonavir , nelfinavir ) have been reported to decrease the metabolism of <e20> drug2 </e20> , resulting in higher plasma levels .
mechanism	<e11> drug1 </e11> may interfere with the absorption of certain drugs ( e , g , , furosemide , nonsteroidal _ anti - inflammatory _ drugs , salicylates , <e20> drug2 </e20> ) by decreasing the serum levels of these drugs .
mechanism	substances that are metabolized by cyp3a4 ( eg , alprazolam , fluoxetine , fluvoxamine , drug1 , sertraline , <e10> drug1 </e10> , drug1 _ hcl ) may increase plasma levels of <e20> drug2 </e20> , resulting in a reduction in efficacy of the drug .
mechanism	however , other published studies have shown that <e12> drug1 </e12> decrease <e20> drug2 </e20> uptake , possibly by competing for binding sites .
mechanism	antifungals : in vitro data from two in vivo studies indicate that <e10> drug1 </e10> significantly decreases the half - life of <e20> drug2 </e20> and drug1 .
mechanism	presumably , <e10> drug1 </e10> may also decrease the metabolism of <e20> drug2 </e20> and therefore , its effectiveness .
mechanism	<e12> drug1 </e12> , sulfonamides , and corticosteroids may interfere with the metabolism of <e20> drug2 </e20> , resulting in elevated plasma levels .
mechanism	however , in a single study , <e10> drug1 </e10> was reported to decrease the <e20> drug2 </e20> clearance by about # % .
mechanism	plasma levels of <e10> drug1 </e10> are increased when patients are treated with an <e22> drug2 </e22> .
mechanism	aspirin : in an in vitro study , <e10> drug1 </e10> significantly decreased the clearance of <e20> drug2 </e20> , and the half - life was increased by approximately 40 % .
mechanism	drug1 : <e10> drug1 </e10> may reduce the absorption of <e20> drug2 </e20> and may reduce the activity of other drug2 - containing preparations .
mechanism	phenytoin / drug1 : <e10> drug1 </e10> increases the clearance of <e20> drug2 </e20> by 4 % and a concentration of drug2 which is approximately 2 to 3 times the active concentration of the parent drug , the effective concentration , increases the clearance of drug2 by approximately 25 % and increases the clearance of phenobarbital by approximately 3 % .
mechanism	treatment with <e11> drug1 </e11> increases the clearance of <e20> drug2 </e20> by twofold and increases the clearance of furosemide by approximately 30 % with concomitant decreases in the renal excretion of these drugs .
mechanism	rifampin : co - administration of <e10> drug1 </e10> with <e20> drug2 </e20> decreased the auc of drug2 by 25 % ( p = # ) .
mechanism	<e10> drug1 </e10> at a dose of # mg / kg / day for # days has been shown to decrease the metabolism of <e20> drug2 </e20> .
mechanism	protein binding in vitro data indicate that the plasma concentrations of <e10> drug1 </e10> are reduced by up to 55 % after coadministration of <e20> drug2 </e20> , dapsone , or amphotericin _ b .
mechanism	( 1968 , 1970 ) , the auc of <e10> drug1 </e10> was significantly increased by # % and # % for diltiazem and <e20> drug2 </e20> , respectively .
mechanism	- drug1 : <e10> drug1 </e10> reduces the absorption of <e20> drug2 </e20> .
mechanism	<e11> drug1 </e11> significantly decreased <e20> drug2 </e20> uptake in c2c12 cells by 63 % .
mechanism	absorption of <e12> drug1 </e12> may be enhanced by <e20> drug2 </e20> and theophylline .
mechanism	ethanol : clinical evidence indicates that <e10> drug1 </e10> increases the plasma concentrations of <e20> drug2 </e20> , clarithromycin , propranolol , phenobarbital , and some cephalosporins .
mechanism	drug1 : <e10> drug1 </e10> reduces the hepatic metabolism of <e20> drug2 </e20> by increasing the levels of triazolam , alprazolam , and triazolam _ hydrochloride .
mechanism	therefore , <e10> drug1 </e10> may decrease the clearance of corticosteroids and / or <e20> drug2 </e20> .
mechanism	the mechanism for this is unknown , but it has been reported that <e10> drug1 </e10> may interfere with the metabolism of <e20> drug2 </e20> , resulting in elevated levels of the parent and / or metabolite , drug2 .
mechanism	when used in a single daily dose of <e10> drug1 </e10> # mg , <e20> drug2 </e20> # mg decreased by approximately 50 % and drug1 # mg decreased by approximately 30 % .
mechanism	although specific studies have not been conducted , it is likely that co - administration of <e10> drug1 </e10> may increase the blood concentrations of <e20> drug2 </e20> .
mechanism	hepatic enzyme inducers , including <e10> drug1 </e10> , valproic _ acid , phenobarbital , phenytoin , carbamazepine , and theophylline , inhibit the metabolism of <e20> drug2 </e20> .
mechanism	agents that are cyp3a4 substrates ( eg , ketoconazole , itraconazole , ritonavir , <e10> drug1 </e10> , indinavir , nelfinavir , saquinavir , indinavir , indinavir / cefvir , itraconazole , ritonavir , saquinavir , itraconazole ) may reduce the bioavailability of <e20> drug2 </e20> .
mechanism	<e10> drug1 </e10> and zinc have been shown to inhibit the absorption of <e20> drug2 </e20> .
mechanism	<e10> drug1 </e10> may increase the absorption of some <e22> drug2 </e22> .
mechanism	quinidine , <e10> drug1 </e10> , and sulfasalazine may decrease the bioavailability of <e20> drug2 </e20> .
mechanism	the gastrointestinal absorption of <e10> drug1 </e10> is decreased when administered concurrently with <e20> drug2 </e20> .
mechanism	<e10> drug1 </e10> has been shown to reduce the clearance of cyclosporine , <e20> drug2 </e20> , and digoxin .
mechanism	based on total - body clearance data , the metabolism of <e10> drug1 </e10> is altered by <e20> drug2 </e20> .
mechanism	another oral azole _ antifungal such as <e11> drug1 </e11> has been reported to decrease the metabolism of <e20> drug2 </e20> .
mechanism	increasing the drug1 plasma concentration by increasing plasma <e10> drug1 </e10> levels increases plasma concentrations of <e20> drug2 </e20> and concomitantly decreases half - life .
mechanism	plasma levels of <e10> drug1 </e10> are significantly decreased in patients treated concomitantly with <e20> drug2 </e20> or drug2 derivatives , and the recommended dose of drug1 is # mg / day .
mechanism	benzodiazepines : combination <e10> drug1 </e10> and benzodiazepines ( alprazolam , triazolam , <e20> drug2 </e20> ) increase the plasma concentrations of the target drug .
mechanism	the absorption of <e10> drug1 </e10> decreased by 62 % with <e20> drug2 </e20> coadministration , and the auc of drug1 increased by 18 % and the cmax by 14 % .
mechanism	urinary acidifying agents ( e , g , , <e10> drug1 </e10> ) increase the absorption of <e20> drug2 </e20> .
mechanism	antacids : in vitro , <e10> drug1 </e10> caused a concentration - dependent inhibition of <e20> drug1 _ hydrochloride </e20> ( corticotropin , 50 micrograms / ml ) absorption , while it did not affect the absorption of either dexamethasone ( 1 micrograms / ml ) or 5 - fluorouracil ( 100 micrograms / ml ) .
mechanism	midazolam : <e10> drug1 </e10> increased the clearance of <e20> drug2 </e20> by 20 % and decreased its bioavailability by 35 % .
mechanism	also , concomitant administration of <e10> drug1 </e10> and <e20> drug2 </e20> at recommended doses will increase the clearance of drug1 by approximately 10 % .
mechanism	drug1 : <e10> drug1 </e10> may inhibit metabolism of <e20> drug2 </e20> by blocking the cytochrome p450 3a4 ( cyp3a4 ) pathway .
mechanism	agents that induce cytochrome p450 3a4 activity ( e , g , , <e10> drug1 </e10> , carbamazepine , diazepam , phenobarbital , drug1 _ hydrochloride , cisapride , disopyramide ) increase the metabolism of <e20> drug2 </e20> and decrease the clearance of drug2 .
mechanism	cytochrome p - 450 inducers , such as fluconazole , <e10> drug1 </e10> , and itraconazole may increase <e20> drug2 </e20> plasma concentrations by inhibiting cyp3a4 .
mechanism	agents that induce hepatic enzyme activity ( such as <e10> drug1 </e10> , phenytoin , or phenytoin _ sulfate ) may reduce the clearance of <e20> drug2 </e20> and increase drug2 blood levels .
mechanism	antidepressants : in one study , the addition of <e10> drug1 </e10> # mg to an ssri ( e , g , , fluoxetine , fluvoxamine , paroxetine , sertraline , venlafaxine ) significantly increased the plasma concentration of <e20> drug2 </e20> , a serotonin reuptake inhibitor .
mechanism	multivalent cation - containing products : in vitro data indicate that the clearance of <e10> drug1 </e10> may be reduced by concomitant use of <e20> drug2 </e20> and some multivalent cation - containing products .
mechanism	apparent oral clearance was determined to be significantly increased when <e10> drug1 </e10> was coadministered with <e20> drug2 </e20> .
mechanism	plasma levels of <e10> drug1 </e10> increased approximately twofold when coadministered with <e20> drug2 </e20> .
mechanism	concomitant administration of <e10> drug1 </e10> and <e20> drug2 </e20> resulted in a mean increase in auc of ~ 14 % for both drugs , whereas cimetidine resulted in a 20 % decrease in auc of drug2 .
mechanism	limited data in rats indicate that <e10> drug1 </e10> at # mg / day decreased the clearance of <e20> drug2 </e20> and increased the clearance of ketoconazole .
mechanism	the absorption of <e10> drug1 </e10> was reduced by 54 % when coadministered with <e20> drug2 </e20> .
mechanism	drug1 : <e10> drug1 </e10> increases the clearance of drug2 and <e20> drug2 </e20> and may increase the half - life of these drugs .
mechanism	inhibitors of cyp1a2 : drug1 : <e10> drug1 </e10> may increase the metabolism of <e20> drug2 </e20> .
mechanism	<e10> drug1 </e10> significantly reduced the rate of <e20> drug2 </e20> metabolism .
mechanism	erythromycin and drug2 : clinical studies in healthy volunteers have shown a dose - dependent reduction of <e10> drug1 </e10> clearance when <e20> drug2 </e20> was co - administered with these agents .
mechanism	oral <e10> drug1 </e10> sulfate treatment significantly decreased the clearance of <e20> drug2 </e20> , increased the clearance of digoxin and did not affect the clearance of carbamazepine .
mechanism	reciprocal interactions may occur when <e10> drug1 </e10> is given concomitantly with <e20> drug2 </e20> .
mechanism	valproate : <e10> drug1 </e10> decreased the clearance of <e20> drug2 </e20> by approximately 50 % .
mechanism	in # other studies , <e10> drug1 </e10> has been shown to decrease the metabolism of <e20> drug2 </e20> in the liver .
mechanism	<e10> drug1 </e10> reduced the auc of <e20> drug2 </e20> by 19 % , decreased the auc of rifabutin by 17 % , and increased the auc of rifabutin by 9 % .
mechanism	<e10> drug1 </e10> may inhibit the metabolism of <e20> drug2 </e20> , resulting in a higher plasma level of the latter .
mechanism	these studies indicate that <e10> drug1 </e10> may enhance the metabolism of <e20> drug2 </e20> or other potentially potent drug2 toxicants , which may potentially increase serum drug2 concentrations and increase drug2 toxicity .
mechanism	however , other published reports have shown that the auc of <e10> drug1 </e10> was significantly decreased in patients receiving <e20> drug2 </e20> .
mechanism	withdrawal of <e10> drug1 </e10> from the diet may increase the clearance of <e20> drug2 </e20> .
mechanism	drug1 : <e10> drug1 </e10> may inhibit <e20> drug2 </e20> absorption resulting in less methylation of c - ia and the subsequent increase in c - ia levels .
mechanism	oral <e10> drug1 </e10> has been shown to decrease the absorption of oral <e20> drug2 </e20> .
mechanism	because oral <e12> drug1 </e12> may interfere with absorption of <e20> drug2 </e20> , a change in the rifampin dose may be necessary .
mechanism	because drug2 is a hepatic enzyme , <e10> drug1 </e10> administration may cause a decrease in the clearance of <e20> drug2 </e20> .
mechanism	in vitro studies have shown that <e10> drug1 </e10> reduced the absorption of <e20> drug2 </e20> by 50 % .
mechanism	after multiple dosing , the <e12> drug1 </e12> demonstrated a tendency to increase the clearance of <e20> drug2 </e20> .
mechanism	absorption of <e10> drug1 </e10> may be enhanced by concurrent administration of <e20> drug2 </e20> , an immunosuppressive drug , and theophylline , a diuretic .
mechanism	<e10> drug1 </e10> - containing preparations ( eg , antacids ) may cause a decrease in the absorption of <e20> drug2 </e20> and therefore may increase the pharmacokinetics of drug2 .
mechanism	the plasma concentration of <e10> drug1 </e10> was decreased by approximately 50 % when administered in combination with <e20> drug2 </e20> .
mechanism	the absorption of <e10> drug1 </e10> is increased by <e20> drug2 </e20> .
mechanism	in addition , other agents that are metabolized by cyp3a4 ( eg , quinolones , cimetidine , clarithromycin , nefazodone , troleandomycin , <e10> drug1 </e10> , isoniazid , ritonavir , saquinavir , telithromycin ) may decrease plasma concentrations of <e20> drug2 </e20> .
mechanism	the most commonly reported drug interactions associated with <e10> drug1 </e10> include increases in <e20> drug2 </e20> serum concentrations , which may result in a significant decrease in the half - life of drug1 .
mechanism	antacids , kaolin _ glass , and other gastric contents containing iron or <e10> drug1 </e10> may increase the absorption of <e20> drug2 </e20> .
mechanism	agents that are primarily metabolized by cyp2c9 ( eg , quinidine , rifampin , fluoxetine , theophylline , <e10> drug1 </e10> , and alfentanil ) may increase plasma concentrations of <e20> drug2 </e20> .
mechanism	ethosuximide : <e12> drug1 </e12> may increase the clearance of <e20> drug2 </e20> , resulting in decreased bioavailability and increased systemic exposure .
mechanism	<e10> drug1 </e10> increases the plasma levels of <e20> drug2 </e20> by 50 % .
mechanism	cimetidine : in vitro data indicate that <e10> drug1 </e10> inhibits the metabolism of <e20> drug2 </e20> and that it may be possible to increase the oral bioavailability of drug1 by altering its metabolism .
mechanism	drugs which induce cyp3a4 activity ( eg , alprazolam , cyclosporine , carbamazepine , <e10> drug1 </e10> , bromocriptine , clarithromycin , flecainide , lovastatin , pimozide , quinine , saquinavir , telithromycin , triazolam ) may increase the clearance of <e20> drug2 </e20> , resulting in a decrease in serum concentrations of drug2 .
mechanism	systemic exposure to <e10> drug1 </e10> may be reduced by concurrent administration of <e20> drug2 </e20> .
mechanism	a study in normal volunteers demonstrated that <e10> drug1 </e10> ( 10 mg ) significantly reduced the auc of <e20> drug2 </e20> by a mean of 30 % .
mechanism	erythromycin : in vitro data indicate that <e10> drug1 </e10> may decrease the pharmacokinetics of <e20> drug2 </e20> , resulting in a higher plasma concentration .
mechanism	while no in vitro studies have been done to determine if these concomitant <e12> drug1 </e12> decrease the renal clearance of <e20> drug2 </e20> , it is possible that the increase in renal clearance may be an indirect consequence of the decrease in the elimination rate of drug2 due to concomitant use of an oral hypoglycemic _ agent ( granisetron ) .
mechanism	the absorption of <e10> drug1 </e10> is reduced by # - fold when coadministered with <e20> drug2 </e20> and vitamin _ b6 .
mechanism	sulindac : the concomitant use of <e10> drug1 </e10> with <e20> drug2 </e20> significantly reduced the clearance of drug2 .
mechanism	increasing the <e10> drug1 </e10> dose increases the clearance of <e20> drug2 </e20> , resulting in an increase in plasma levels and concomitant increase in half - life .
mechanism	drug1 : <e10> drug1 </e10> may increase the serum concentrations of <e20> drug2 </e20> .
mechanism	erythromycin and <e10> drug1 </e10> inhibited the metabolism of <e20> drug2 </e20> .
mechanism	drugs which induce hepatic metabolism of <e11> drug1 </e11> include : carbamazepine , cyclosporine , tacrolimus , disopyramide , diazepam , diltiazem , haloperidol , methadone , phenytoin , <e20> drug2 </e20> , theophylline , triazolam , theophylline _ hcl , and isoniazid .
mechanism	drug1 : administration of <e10> drug1 </e10> may prolong the half - life of <e20> drug2 </e20> .
mechanism	cimetidine , caffeine , and <e10> drug1 </e10> may increase <e20> drug2 </e20> levels by inhibiting sulfate - reducing enzymes .
mechanism	short - term pharmacokinetic studies in healthy subjects revealed a 20 % reduction in cmax and a 40 % decrease in auc with <e10> drug1 </e10> and <e20> drug1 </e20> coadministration .
mechanism	elevated plasma levels of <e10> drug1 </e10> have been reported with the concomitant administration of oral <e20> drug2 </e20> and some other oral anticoagulants .
mechanism	<e10> drug1 </e10> decreased the plasma levels of <e20> drug2 </e20> by 47 % .
mechanism	<e10> drug1 </e10> may increase plasma concentrations of <e20> drug2 </e20> and other known inhibitors of cytochrome p450 .
mechanism	digoxin : in vitro , <e10> drug1 </e10> markedly decreased <e20> drug2 </e20> binding to in vitro phosphorylated extracellular domains of p53 , with a possible relevance to the pharmacokinetics of drug2 .
mechanism	quinidine , verapamil , <e10> drug1 </e10> , and fluoxetine inhibit the metabolism of <e20> drug2 </e20> , causing a decrease in the bioavailability of drug2 .
mechanism	uricosuric _ drugs , such as <e10> drug1 </e10> , may have an increased exposure to the <e22> drug2 </e22> .
mechanism	specific effects of folic _ acid : there is one report in which <e10> drug1 </e10> decreased the serum concentrations of <e20> drug2 </e20> and , to a similar extent , the concentrations of vitamin b12 and vitamin a in subjects taking these drugs concomitantly .
mechanism	ephedrine : <e10> drug1 </e10> has been reported to decrease the metabolism of <e20> drug2 </e20> , resulting in a 5 % decrease in plasma drug2 concentrations .
mechanism	drug1 : <e10> drug1 </e10> significantly increases the clearance of <e20> drug2 </e20> , an hmg - coa _ reductase _ inhibitor .
mechanism	antibiotics : in vitro data suggest that oral <e12> drug1 </e12> , including ampicillin and tetracycline , may diminish the renal clearance of <e20> drug2 </e20> .
mechanism	<e10> drug1 </e10> may enhance the metabolism of <e20> drug2 </e20> .
mechanism	<e10> drug1 </e10> may increase the clearance of <e20> drug2 </e20> , resulting in decreased plasma levels of this medication .
mechanism	<e10> drug1 </e10> increased the clearance of <e20> drug2 </e20> by about twofold , and the clearance of ketoconazole and phenytoin by about 20 % and 60 % , respectively .
mechanism	during administration of <e10> drug1 </e10> , <e20> drug2 </e20> and cimetidine plasma concentrations are decreased by approx . 50 % , and a reduction of approx . 30 % in the auc of cimetidine is observed , compared to the plasma concentrations at # mg / kg .
mechanism	leucovorin : the oral absorption of <e10> drug1 </e10> is impaired by coadministration with <e20> drug2 </e20> and has been demonstrated to result in increased plasma levels of drug1 and its active metabolite drug1 sulfone .
mechanism	<e10> drug1 </e10> may enhance the absorption of <e20> drug2 </e20> or its derivatives , especially in patients taking cyclosporine or tacrolimus .
mechanism	plasma concentrations of <e10> drug1 </e10> are increased by <e20> drug2 </e20> and decreased by the drug1 protease _ inhibitor diltiazem , suggesting that drug1 is a target of the enzyme inhibitors for the treatment of diabetes .
mechanism	pharmacokinetic studies have demonstrated that <e10> drug1 </e10> increases the exposure of <e20> drug2 </e20> and that drug1 increases the rate of drug2 elimination .
mechanism	coadministration of <e11> drug1 </e11> # mg with <e20> drug2 </e20> at # mg reduced the auc by 41 % ( p = 0 . 004 ) and the cmax by 37 % ( p = 0 . 001 ) compared to placebo .
mechanism	protein binding in vitro studies have shown that <e10> drug1 </e10> increases the binding of <e20> drug2 </e20> , carbamazepine , and cisapride to protein .
mechanism	propantheline and <e10> drug1 </e10> markedly inhibit <e20> drug2 </e20> metabolism , resulting in increased plasma concentrations and absorption .
mechanism	<e10> drug1 </e10> inhibited <e20> drug2 </e20> binding with an auc of 14 % and 24 % inhibition of drug2 auc in serum and urine .
mechanism	drug1 : <e10> drug1 </e10> decreased the auc of <e20> drug2 </e20> by approximately 50 % .
mechanism	plasma exposure ( auc ) of <e10> drug1 </e10> was higher with concomitant administration of <e20> drug2 </e20> than with drug2 alone ( 3 - fold increase in drug1 auc ) .
mechanism	drug1 : <e10> drug1 </e10> may decrease the renal clearance of <e20> drug2 </e20> , and therefore the dose requirement .
mechanism	<e11> drug1 </e11> decreased plasma levels of <e20> drug2 </e20> and its active metabolite enoxacin by 53 % and 68 % , respectively .
mechanism	<e10> drug1 </e10> inhibited the metabolism of <e20> drug2 </e20> to produce a drug concentration decrease in blood serum and a decreased half - life in urine .
mechanism	clofibric _ acid : combination <e12> drug1 </e12> may decrease plasma levels of <e20> drug2 </e20> .
mechanism	drugs that may increase plasma concentrations of <e10> drug1 </e10> include certain antibiotics ( e , g , , ampicillin , tetracycline , <e20> drug2 </e20> , clindamycin , colistin , clindamycin , chloramphenicol , cisapride , dapsone , dipyridamole , diflunisal , flecainide , miconazole , nelfinavir , ritonavir , saquinavir , troleandomycin , telithromycin , tobramycin , theophylline , and zidovudine ) and monoamine _ oxidase _ inhibitors , as well as some tricyclic _ antidepressants and certain quinidine _ derivatives .
mechanism	alcohol : it is possible that the increase in <e10> drug1 </e10> may decrease the serum <e20> drug2 </e20> levels , which have been shown to increase when patients are treated with oral anticonvulsants .
mechanism	plasma levels of <e10> drug1 </e10> were significantly increased when it was given with <e20> drug1 </e20> , but not when it was given with either dexamethasone or a beta - adrenergic _ blocking _ agent .
mechanism	drug1 : <e10> drug1 </e10> , like other statins , reduces the hepatic metabolism of <e20> drug2 </e20> .
mechanism	<e12> drug1 </e12> may interfere with the metabolism of oral <e22> drug2 </e22> .
mechanism	total body clearance of <e10> drug1 </e10> is increased approximately 5 - fold by combination with a high dose of <e20> drug2 </e20> .
mechanism	carbamazepine : <e11> drug1 </e11> has been shown to decrease the clearance of <e20> drug2 </e20> .
mechanism	phenytoin / phenobarbital / warfarin : <e10> drug1 </e10> may enhance the metabolism of <e20> drug2 </e20> , phenobarbital , or warfarin , resulting in elevated plasma levels of these medications .
mechanism	drug interactions with d , h , e , _ 45 : a single oral dose of <e11> drug1 </e11> # mg in healthy volunteers produced a mean decrease of 38 % in plasma <e20> drug2 </e20> levels , which was most pronounced at # mg ( p = # ) .
mechanism	rifampin : coadministration of <e10> drug1 </e10> # mg with # mg of <e20> drug2 </e20> resulted in a significant increase in drug2 exposure and a 50 % decrease in plasma concentrations .
mechanism	<e11> drug1 </e11> has been reported to reduce the plasma concentrations of <e20> drug2 </e20> by up to 50 % .
mechanism	in vitro , <e10> drug1 </e10> reduces the exposure of <e20> drug2 </e20> and ampicillin to 3 % and 4 % , respectively .
mechanism	drug1 : <e10> drug1 </e10> increases the metabolism of <e20> drug2 </e20> by increasing hepatic and renal activity .
mechanism	<e10> drug1 </e10> decreased the <e20> drug2 </e20> plasma concentrations by 53 % .
mechanism	probenecid : the dose of <e10> drug1 </e10> that increases plasma <e20> drug2 </e20> concentrations by 10 % is 10 times higher than that of non - cytochrome p4503a4 substrates .
mechanism	inhibitors of cyp3a4 ( eg , ketoconazole , itraconazole , <e10> drug1 </e10> , erythromycin , clarithromycin ) may increase the clearance of <e20> drug2 </e20> .
mechanism	fluconazole : concomitant administration of <e10> drug1 </e10> and <e20> drug2 </e20> increased drug2 plasma levels by approximately 7 % .
mechanism	increasing the <e10> drug1 </e10> plasma concentrations may also result in decreased <e20> drug2 </e20> clearance and increased concomitant serum levels .
mechanism	<e10> drug1 </e10> salts reduce the renal clearance of <e20> drug2 </e20> , but increase the renal clearance of disopyramide and phenytoin .
mechanism	although specific studies are not available , <e10> drug1 </e10> and other related drugs , including macrolide _ antibiotics , may interfere with the metabolism of <e20> drug2 </e20> , resulting in elevated plasma levels .
mechanism	the mean clearances of <e10> drug1 </e10> , rifabutin , and nelfinavir were 6 , 11 , and 6 % higher , respectively , when coadministered with <e20> drug2 </e20> than when administered alone .
mechanism	drugs which inhibit cyp3a4 ( eg , <e10> drug1 </e10> , fluoxetine , paroxetine , theophylline , quinidine , fluvoxamine , cimetidine , quinidine , triazolam , valproate , alfentanil ) may increase the clearance of <e20> drug2 </e20> .
mechanism	when used in combination with <e10> drug1 </e10> , there is a reduction in the clearance of <e20> drug2 </e20> .
mechanism	drug1 : <e10> drug1 </e10> may decrease the absorption of <e20> drug2 </e20> and other oral hypoglycemic _ agents , resulting in a lower therapeutic dose .
mechanism	- drugs that induce cyp3a4 activity ( eg , <e10> drug1 </e10> , phenobarbital , phenytoin , alfentanil , phenytoin _ hydrochloride , and rifampin ) increase the plasma concentration of <e20> drug2 </e20> .
mechanism	drug1 : <e10> drug1 </e10> , at the dose of # mg / kg / day , reduced the elimination of <e20> drug2 </e20> ( 16 mg / kg / day ) by 25 % and halved the elimination of propranolol ( 10 mg / kg / day ) .
mechanism	<e10> drug1 </e10> also increases <e20> drug2 </e20> plasma levels by about 50 % .
mechanism	oral contraceptives : <e12> drug1 </e12> have been shown to reduce the metabolism of oral <e22> drug2 </e22> .
mechanism	other potentially important drug interactions : nonsteroidal _ anti - inflammatory _ drugs : concurrent administration of <e10> drug1 </e10> and other potentially important anti - inflammatory _ drugs ( corticosteroids , indomethacin , <e20> drug2 </e20> , triamterene , bromocriptine , and terfenadine ) may result in decreased systemic exposure to a possible toxic dose of either of these drugs .
mechanism	<e10> drug1 </e10> has been reported to inhibit the metabolism of other <e22> drug2 </e22> .
mechanism	agents with increased sustained release : <e10> drug1 </e10> , nelfinavir , ritonavir , and erythromycin decrease the rate of absorption of the <e20> drug2 </e20> , and therefore may increase the half - life .
mechanism	<e11> drug1 </e11> # mg / kg of # days was found to reduce the plasma concentrations of <e20> drug2 </e20> by 48 % and 40 % , respectively .
mechanism	inhibitors of cyp3a4 ( alfentanil , <e10> drug1 </e10> , disopyramide ) have been reported to cause increases in plasma concentrations of <e20> drug2 </e20> .
mechanism	drug1 , ranitidine : <e10> drug1 </e10> may increase the clearance of <e20> drug2 </e20> .
mechanism	the interaction is likely to be significant since <e10> drug1 </e10> inhibits <e20> drug2 </e20> metabolism by inhibiting cyp3a4 .
mechanism	results of preliminary studies indicate that the clearance of <e10> drug1 </e10> can be significantly increased by the addition of <e20> drug2 </e20> to daily dosing , which was observed in volunteers taking either the single oral dose of drug1 or the recommended daily dose of drug2 for # days prior to the administration of the study drug .
mechanism	ketoconazole : co - administration of <e10> drug1 </e10> and <e20> drug2 </e20> decreased auc values by a mean of 6 % .
mechanism	probenecid : as a consequence of <e10> drug1 </e10> , plasma concentrations of <e20> drug2 </e20> increased by a mean of 18 % and 17 % , respectively , resulting in a 16 % and 18 % increase in auc values for drug2 and benzodiazepines , respectively .
mechanism	corticosteroids : a 10 - day regimen of <e10> drug1 </e10> # mg daily resulted in a decrease of <e20> drug2 </e20> from # mg to # mg and a decrease of alprazolam from # mg to # mg .
mechanism	phenytoin , <e10> drug1 </e10> , and tacrolimus decrease <e20> drug2 </e20> serum concentrations by inhibiting cyp3a4 activity .
mechanism	the absorption of <e10> drug1 </e10> is decreased by <e20> drug2 </e20> .
mechanism	substances that are cyp 3a4 substrates ( eg , alfentanil , terfenadine , and <e10> drug1 </e10> ) may increase plasma concentrations of <e20> drug2 </e20> .
mechanism	drug1 : <e10> drug1 </e10> increases the clearance of <e20> drug2 </e20> .
mechanism	products containing <e10> drug1 </e10> , clarithromycin , or erythromycin may reduce or discontinue the absorption of <e20> drug2 </e20> , resulting in decreased drug2 serum concentrations .
mechanism	drug1 : <e10> drug1 </e10> may interfere with absorption of <e20> drug2 </e20> .
mechanism	absorption of <e12> drug1 </e12> is enhanced by <e20> drug2 </e20> , a cationic cationic binding protein ( and by a number of drug1 and other cationic _ binding _ agents ) .
mechanism	diltiazem : in a study in healthy volunteers , # mg of <e10> drug1 </e10> . # hours after a single dose of # mg <e20> drug2 </e20> , the plasma concentration of drug2 was reduced by 58 % and the auc by 58 % .
mechanism	drugs which inhibit cyp3a4 ( eg , ketoconazole , itraconazole , ritonavir , drug1 , indinavir , <e10> drug1 </e10> , clarithromycin , saquinavir , telithromycin , troleandomycin , troleandomycin s , troleandomycin s , indinavir , ritonavir , saquinavir , troleandomycin , indinavir ) may reduce the bioavailability of <e20> drug2 </e20> .
mechanism	agents that are cyp3a4 inhibitors ( eg , ketoconazole , itraconazole , clarithromycin , ritonavir , drug2 , <e10> drug1 </e10> , saquinavir , saquinavir , telithromycin , troleandomycin , troleandomycin , troleandomycin , valdecoxib , drug1 , saquinavir , troleandomycin ) increase the clearance of <e20> drug2 </e20> and may require increases in drug2 plasma concentrations to achieve a desired response .
mechanism	limited data in humans suggest that <e10> drug1 </e10> may interfere with the metabolism of warfarin and <e20> drug2 </e20> , resulting in elevated blood levels .
mechanism	warfarin : <e12> drug1 </e12> , including cimetidine , may increase the clearance of <e22> drug2 </e22> .
mechanism	in vitro , <e10> drug1 </e10> and erythromycin inhibit <e20> drug2 </e20> uptake and in vivo , the combination of drug2 with the cyp3a4 inhibitor , cisapride , results in an increase in clearance of drug2 .
mechanism	drug1 : <e10> drug1 </e10> has been shown to decrease the absorption of <e20> drug2 </e20> and its metabolites , thereby potentially increasing the systemic exposure of drug2 and its active metabolite .
mechanism	antacids and drug2 : <e10> drug1 </e10> may decrease the absorption of <e20> drug2 </e20> .
mechanism	total body clearance of <e11> drug1 </e11> was reduced by 11 % and was reduced by 23 % with concurrent use of a single <e20> drug2 </e20> dose .
mechanism	lithium : in a study in healthy volunteers , <e10> drug1 </e10> decreased the levels of <e20> drug1 </e20> and decreased the metabolic activity of drug1 .
mechanism	oral <e10> drug1 </e10> can interfere with the absorption of other <e22> drug2 </e22> .
mechanism	<e10> drug1 </e10> may decrease plasma <e20> drug2 </e20> concentrations and increase the half - life of drug2 .
mechanism	cholestyramine and charcoal or <e10> drug1 </e10> may inhibit hepatic metabolism of <e20> drug2 </e20> .
mechanism	<e10> drug1 </e10> has been shown to increase the clearance of <e20> drug2 </e20> by about 50 % .
mechanism	antibiotics : in a study in healthy volunteers , the half - life of <e11> drug1 </e11> increased by 20 % and the elimination half - life decreased by 20 % when the recommended daily dose of <e20> drug2 </e20> was doubled .
mechanism	cyclosporin : reports have shown that <e10> drug1 </e10> increases the half - life of <e20> drug2 </e20> .
mechanism	plasma exposure ( auc ) of <e10> drug1 </e10> was decreased by approximately 40 % when coadministered with <e20> drug1 </e20> and a macrolide _ antibiotic ( ciprofloxacin ) .
mechanism	- drugs that induce hepatic enzymes such as <e10> drug1 </e10> , carbamazepine , and phenobarbital may reduce the clearance of <e20> drug2 </e20> .
mechanism	<e11> drug1 </e11> decreased the auc and cmax of <e20> drug2 </e20> by 18 % and 31 % , respectively .
mechanism	protease _ inhibitors : in the presence of <e10> drug1 </e10> , a decrease in the rate of reduction of <e20> drug2 </e20> was observed .
mechanism	steady - state <e10> drug1 </e10> plasma concentrations are decreased by approximately 20 % following administration of <e20> drug2 </e20> .
mechanism	digoxin : when <e10> drug1 </e10> is administered concurrently with <e20> drug2 </e20> , the mean alfenta auc is decreased by # % .
mechanism	<e10> drug1 </e10> may increase <e20> drug2 </e20> clearance , resulting in elevated levels of serum drug2 .
mechanism	plasma concentrations of <e10> drug1 </e10> are increased when <e20> drug2 </e20> is used concomitantly .
mechanism	the increase of <e10> drug1 </e10> concentrations in the presence of <e20> drug2 </e20> may be potentiated .
mechanism	cytochrome p - 450 inducers , including <e10> drug1 </e10> , cimetidine , itraconazole , and drug1 , inhibit <e20> drug2 </e20> metabolism , resulting in a decrease in serum and urine levels of drug2 .
mechanism	in # other patients , increased plasma levels of <e10> drug1 </e10> have been observed when <e20> drug2 </e20> therapy was initiated , a possible drug interaction .
mechanism	inhibitors of cyp3a4 ( phenytoin , <e10> drug1 </e10> , fluoxetine , paroxetine , sertraline , alfentanil , fluvoxamine , risperidone , quinidine , pimozide ) have been reported to inhibit <e20> drug2 </e20> metabolism .
mechanism	<e10> drug1 </e10> may potentiate the metabolism of <e20> drug2 </e20> .
mechanism	drugs that induce hepatic enzyme systems ( e , g , , amiodarone , <e10> drug1 </e10> ) may increase the clearance of <e20> drug2 </e20> .
mechanism	agents that are inhibitors of cyp3a4 ( e , g , , ketoconazole , itraconazole , ritonavir , clarithromycin , indinavir , <e10> drug1 </e10> , drug2 , saquinavir , saquinavir / interferon - alfa , telithromycin ) have been shown to prolong the half - life of <e20> drug2 </e20> by 50 % or more and to prolong the half - life of itraconazole by 45 % .
mechanism	phenobarbital : it has been reported that <e10> drug1 </e10> may inhibit the metabolism of <e20> drug2 </e20> .
mechanism	capsules <e11> drug1 </e11> may increase the bioavailability of <e20> drug2 </e20> and other potent cyp3a4 inhibitors such as , but not limited to , isoniazid , phenytoin , carbamazepine , cimetidine , cyclosporine , tacrolimus , disopyramide , ketoconazole , phenytoin , alfentanyl , cisapride , disulfiram , ergot _ derivatives , ketoconazole , lovastatin , rifampin , saquinavir , theophylline , temazepam , and theophylline _ citrate .
mechanism	use with allopurinol : <e10> drug1 </e10> may increase the plasma concentrations of <e20> drug2 </e20> .
mechanism	<e10> drug1 </e10> may inhibit the metabolism of <e20> drug2 </e20> .
mechanism	previous studies have shown that <e10> drug1 </e10> decreased the clearance of <e20> drug2 </e20> by 27 % ( ic50 = 47 mg / kg ) .
mechanism	saquinavir : coadministration of <e10> drug1 </e10> with <e20> drug2 </e20> # mg resulted in a 13 % decrease in auc , which was attenuated by # mg drug2 .
mechanism	protein binding inhibitors : <e10> drug1 </e10> has been reported to inhibit <e20> drug2 </e20> , cyclosporine , indinavir , and nelfinavir metabolism .
mechanism	drug1 : <e10> drug1 </e10> decreased the clearance of <e20> drug2 </e20> by increasing the mean plasma concentrations of triazolam by a mean of approximately 20 % .
mechanism	aspirin : concomitant administration of <e11> drug1 </e11> with <e20> drug2 </e20> decreased drug2 auc by 36 % ( p = 0 . 005 ) and cmax by 22 % ( p = 0 . 012 ) compared to drug2 alone .
mechanism	drug1 : <e10> drug1 </e10> may inhibit the metabolism of some <e22> drug2 </e22> , including ceftazidime , resulting in elevated serum levels .
mechanism	the elimination half - life of <e10> drug1 </e10> was increased to 10 days when administered with <e20> drug2 </e20> .
mechanism	co - administration of <e10> drug1 </e10> significantly decreased the plasma levels of <e20> drug2 </e20> .
mechanism	inhibitors of cyp3a4 ( eg , ketoconazole , itraconazole , erythromycin , clarithromycin , ritonavir , indinavir , <e10> drug1 </e10> , telithromycin , troleandomycin ) have been shown to decrease the plasma concentration of <e20> drug2 </e20> by approximately 30 % and may prolong the qt interval on the ecg by approximately 20 % .
mechanism	dicumarol : it is known that <e10> drug1 </e10> may reduce the metabolism of <e20> drug2 </e20> and increase the clearance of cisplatin .
mechanism	drug1 : <e10> drug1 </e10> ( acetaminophen ) has been reported to reduce the bioavailability of <e20> drug2 </e20> .
mechanism	in em individuals , the dose of <e10> drug1 </e10> required to achieve # mg of <e20> drug2 </e20> clearance was increased by # % ( approximately # % ) and the cmax was increased by # % .
mechanism	<e11> drug1 </e11> can reduce the clearance of other oral <e22> drug2 </e22> , thus increasing the risk of systemic bleeding .
mechanism	<e10> drug1 </e10> significantly decreased the auc of <e20> drug2 </e20> by 50 % in a single dose , and increased the auc of drug2 by 20 % in a single dose .
mechanism	drug1 : <e10> drug1 </e10> has been reported to decrease the metabolism of <e20> drug2 </e20> , thus decreasing the half - life of the active compound .
mechanism	- drug1 and erythromycin : <e10> drug1 </e10> and erythromycin inhibit the metabolism of <e20> drug2 </e20> , causing a marked increase in plasma and urine concentrations .
mechanism	cimetidine : in patients receiving <e10> drug1 </e10> concurrently with <e20> drug2 </e20> , the following variables were reduced : ( 1 ) the auc of drug2 , the primary metabolite of drug1 , was reduced by approximately # % ( 47 % decrease ) .
mechanism	drug1 : <e10> drug1 </e10> ( 40 mg / kg bw , s , c , ) had a strong and sustained effect on the elimination of <e20> drug2 </e20> , with the resulting increase in drug2 levels being # % of that observed with other ssris .
mechanism	drug1 : <e10> drug1 </e10> has been reported to inhibit the metabolism of <e20> drug2 </e20> by interfering with cyp3a4 , resulting in decreased plasma levels of drug2 .
mechanism	ketoconazole : when used concomitantly , <e10> drug1 </e10> may increase <e20> drug2 </e20> plasma concentrations .
mechanism	coadministration with compounds that are potent inhibitors of cyp3a4 ( such as ketoconazole and itraconazole , nefazodone , troleandomycin , clarithromycin , erythromycin , ritonavir , <e10> drug1 </e10> , drug1 , indinavir , drug1 , indinavir ) decreased <e20> drug2 </e20> plasma concentrations .
mechanism	quinidine , verapamil , <e10> drug1 </e10> , and drug1 / drug1 _ hcl increases the clearance of <e20> drug2 </e20> , resulting in a decrease in auc .
mechanism	previous studies have shown that <e10> drug1 </e10> can reduce the plasma levels of <e20> drug2 </e20> .
mechanism	<e10> drug1 </e10> decreases the metabolism of <e20> drug2 </e20> by approximately 15 % .
mechanism	terfenadine , <e10> drug1 </e10> , and indinavir inhibit <e20> drug2 </e20> metabolism by inhibiting cytochrome p450 3a4 activity .
mechanism	in a study in normolipidemic subjects with elevated liver alt , a single oral dose of <e10> drug1 </e10> # mg was associated with a 28 % decrease in plasma levels of <e20> drug2 </e20> ( 400 mg ) .
mechanism	an intravenous injection of <e10> drug1 </e10> # mg in a dose of # mg was found to increase the clearance of <e20> drug2 </e20> by 6 % at # hours post injection .
mechanism	this study demonstrates that <e10> drug1 </e10> reduced blood levels of <e20> drug2 </e20> by approximately 36 % .
mechanism	promethazine : coadministration of <e10> drug1 </e10> and <e20> drug2 </e20> significantly reduced the rate of drug1 absorption .
mechanism	drugs which induce cyp3a4 ( eg , cyclosporine , tacrolimus , <e10> drug1 </e10> , drug2 , alfentanil , cisapride , disopyramide , phenobarbital , alfentanil , carbamazepine , carbamazepine and alfentanil ) may increase plasma concentrations of <e20> drug2 </e20> and may therefore require a reduction in dose of drug2 when coadministered with these drugs .
mechanism	the plasma concentration of <e10> drug1 </e10> decreased by approximately 20 % when coadministered with <e20> drug2 </e20> and by approximately 50 % when coadministered with cd - dtpa .
mechanism	administration of <e12> drug1 </e12> may inhibit the metabolism of <e20> drug2 </e20> , resulting in a lower plasma concentration of drug2 .
mechanism	the concomitant use of <e10> drug1 </e10> and <e20> drug2 </e20> resulted in a 1 . 5 - fold increase in auc and cmax values .
mechanism	concomitant use of <e10> drug1 </e10> and <e20> drug2 </e20> increased auc of drug2 by about two - fold , but did not affect the pharmacokinetic profile of drug2 .
mechanism	<e10> drug1 </e10> increased the half - life of <e20> drug1 </e20> by an average of # minutes .
mechanism	drug1 : <e10> drug1 </e10> may increase plasma levels of <e20> drug2 </e20> and cimetidine .
mechanism	similarly , <e10> drug1 </e10> caused a concentration - dependent decrease in the cmax of <e20> drug2 </e20> and a concentration - dependent increase in the auc of drug2 .
mechanism	drug1 : <e10> drug1 </e10> may increase plasma concentrations of <e20> drug2 </e20> by altering its metabolism and absorption .
mechanism	the absorption of <e10> drug1 </e10> is enhanced by <e20> drug2 </e20> .
mechanism	coadministration with compounds that interfere with cyp3a4 activity , such as ketoconazole , itraconazole , ritonavir , erythromycin , indinavir , nefazodone , <e10> drug1 </e10> , saquinavir , and astemizole resulted in increases in plasma levels of <e20> drug2 </e20> and astemizole .
mechanism	studies showed that <e10> drug1 </e10> has the potential to reduce the absorption of other oral <e22> drug2 </e22> , including phenytoin , carbamazepine , triazolam , disopyramide , phenobarbital , and phenytoin .
mechanism	ketoconazole : coadministration of <e10> drug1 </e10> with <e20> drug2 </e20> # mg was associated with a # - fold increase in drug2 exposure .
mechanism	in clinical trials , <e10> drug1 </e10> decreased the clearance of # mg / day of <e20> drug2 </e20> by 42 % ( 6 % observed to be due to increased elimination ) .
mechanism	in renal and cardiac transplant patients , <e10> drug1 </e10> increases plasma concentrations of <e20> drug2 </e20> .
mechanism	multivalent cation - containing products : <e11> drug1 </e11> may increase the plasma concentrations of cation - containing products such as <e20> drug2 </e20> and tacrolimus .
mechanism	human pharmacokinetics data from healthy volunteers who received dosing with <e10> drug1 </e10> # mg once daily for # days have shown a significant increase in clearance of <e20> drug2 </e20> # mg daily , which would result in an approximately 30 % increase in drug2 plasma levels .
mechanism	coadministration with <e10> drug1 </e10> significantly increased the plasma level of <e20> drug1 </e20> by 15 % .
mechanism	use with allopurinol : <e10> drug1 </e10> and similar drugs reduce the clearance of <e20> drug2 </e20> , resulting in an increased plasma level .
mechanism	<e10> drug1 </e10> reduces the absorption of <e20> drug2 </e20> and does not affect the absorption of aminosalicylic _ acid , clarithromycin , lithium , methotrexate , sulfonamides , or tricyclic _ antidepressants .
mechanism	co - medications that induce hepatic enzymes such as <e10> drug1 </e10> or tacrolimus have the potential to increase the clearance of <e20> drug2 </e20> .
mechanism	erythromycin and <e10> drug1 </e10> may increase serum levels of <e20> drug2 </e20> .
mechanism	plasma levels of <e10> drug1 </e10> increased approximately 8 - fold after coadministration of <e20> drug2 </e20> # mg ( the cmax was # ng / ml ) .
mechanism	drug1 : <e10> drug1 </e10> increases <e20> drug2 </e20> clearance by approximately 50 % .
mechanism	<e10> drug1 </e10> has been reported to decrease the clearance of <e20> drug2 </e20> , resulting in increased serum drug2 levels .
mechanism	<e10> drug1 </e10> decreased the exposure of <e20> drug2 </e20> to 7 . 3 % and decreased the total concentration of drug2 to 26 % .
mechanism	<e10> drug1 </e10> and magnesium ( particularly ) may interfere with absorption of <e20> drug2 </e20> , thereby reducing the plasma level of drug2 .
mechanism	inh ( <e10> drug1 </e10> ) binding to the inh receptor is inhibited by <e20> drug2 </e20> .
mechanism	<e10> drug1 </e10> injection increases the clearance of ( e , g , , <e20> drug2 </e20> ) by about two - fold and the half - life of ( e , g , , drug2 ) by about two - fold .
mechanism	<e10> drug1 </e10> has been reported to inhibit the metabolism of <e20> drug2 </e20> , leading to a decrease in the serum levels of drug2 .
mechanism	in a ten - subject study , coadministration of <e10> drug1 </e10> tablets with either <e20> drug2 </e20> ( 50 mg ) or tetracycline ( 50 mg ) tablets resulted in a decrease in auc of both drug1 and tetracycline .
mechanism	uricosuric _ agents : since <e10> drug1 </e10> has been reported to decrease the bioavailability of <e20> drug2 </e20> , the two may interact with each other in a manner that may result in drug2 toxicity .
mechanism	inh ( <e10> drug1 </e10> ) metabolism may be inhibited by <e20> drug2 </e20> and other coumarin _ anticoagulants .
mechanism	the half - life of <e11> drug1 </e11> was prolonged when coadministered with <e20> drug2 </e20> , cimetidine , or anastrozole .
mechanism	<e10> drug1 </e10> significantly inhibits <e20> drug2 </e20> elimination ( p = 0 . 00005 ) in a dose - dependent manner .
mechanism	in vitro studies have shown that <e10> drug1 </e10> can increase the hepatic metabolism of <e20> drug2 </e20> and drug2 / cyclosporine .
mechanism	<e10> drug1 </e10> markedly decreased the binding of <e20> drug2 </e20> to platelets and decreased the binding of cimetidine to platelets .
mechanism	lithium : <e12> drug1 </e12> decrease the bioavailability of <e22> drug2 </e22> .
mechanism	however , <e10> drug1 </e10> increased the mean plasma concentration of <e20> drug2 </e20> and , to a lesser extent , that of the 4 - hydroxy - 2 - methylphenol metabolite .
mechanism	concomitant administration of <e10> drug1 </e10> and <e20> drug2 </e20> produced a 2 - fold increase in drug2 auc .
mechanism	because <e10> drug1 </e10> significantly increased the clearance of <e20> drug2 </e20> , the increase in plasma drug2 concentrations may have resulted in an increased plasma level of theophylline .
mechanism	coadministration of <e10> drug1 </e10> # mg and <e20> drug2 </e20> # mg decreased the auc by about 17 % ( p = 0 . 001 ) .
mechanism	oral <e12> drug1 </e12> may enhance the absorption of <e20> drug2 </e20> by causing a decrease in the renal tubular secretion of drug2 .
mechanism	drugs that cause a rise in serum creatinine ( eg , <e10> drug1 </e10> , doxycycline , amiodarone , drug1 sulfate ) may decrease the renal clearance of <e20> drug2 </e20> .
mechanism	rifampin : coadministration of <e10> drug1 </e10> and <e20> drug2 </e20> ( bromocriptine _ mesylate ) resulted in a decrease in auc of drug1 by # % .
mechanism	methotrexate : <e10> drug1 </e10> ( vitamin _ d ) - containing preparations , such as , for example , the multivitamins and vitamin _ c preparations , may interfere with absorption of <e20> drug2 </e20> .
mechanism	products containing <e10> drug1 </e10> may decrease plasma concentrations of <e20> drug2 </e20> and some nonsteroidal _ anti - inflammatory _ drugs .
mechanism	the clearance of <e10> drug1 </e10> has been reported to be enhanced by <e20> drug2 </e20> .
mechanism	the half - life of <e10> drug1 </e10> was reduced by about two - thirds when coadministered with <e20> drug2 </e20> .
mechanism	drug1 : <e10> drug1 </e10> inhibits the metabolism of <e20> drug2 </e20> and its derivatives by cyp3a4 , and therefore has a possible pharmacokinetic interaction with drug2 .
mechanism	however , the peak plasma concentrations of <e10> drug1 </e10> are exceeded by approximately # - fold in the presence of <e20> drug2 </e20> and in the presence of phenytoin , and by approximately 2 - fold in the presence of lovastatin .
mechanism	since zarontin ( <e10> drug1 </e10> ) and some other nsaids reduce the absorption of <e20> drug2 </e20> , it is possible that they may increase the serum levels of drug2 .
mechanism	drug1 - and aluminum - containing antacids , including <e10> drug1 </e10> , aluminum , and calcium - containing antacids , may interfere with absorption of <e20> drug2 </e20> and cause low serum concentrations of this drug .
mechanism	<e10> drug1 </e10> was reported to decrease the metabolism of <e20> drug2 </e20> .
mechanism	phenytoin : <e12> drug1 </e12> may increase the metabolism of <e20> drug2 </e20> .
mechanism	drug1 : <e10> drug1 </e10> inhibits the metabolism of <e20> drug2 </e20> .
mechanism	the absorption of <e10> drug1 </e10> was enhanced by the concomitant administration of <e20> drug2 </e20> , indicating that drug2 may have a role in increasing the absorption of drug1 .
mechanism	drug1 : <e10> drug1 </e10> has been shown to decrease the pharmacokinetics of other <e22> drug2 </e22> , including carbamazepine , phenobarbital , and alfentanil .
mechanism	although specific studies have not been performed , it is likely that <e10> drug1 </e10> may interfere with the metabolism of <e20> drug2 </e20> by inhibiting cyp2c9 .
mechanism	metformin : in a study in normal volunteers , <e10> drug1 </e10> significantly increased the <e20> drug2 </e20> absorption , with similar effects on drug2 and niacin .
mechanism	in a study of subjects with moderate to severe migraine , the daily dosage of <e10> drug1 </e10> was reduced by approximately 50 % when <e20> drug2 </e20> was used as a prodrug .
mechanism	phenobarbital ( primidone ) and <e10> drug1 </e10> may reduce the clearance of <e20> drug2 </e20> and phenytoin .
mechanism	cimetidine , <e10> drug1 </e10> , or similar drugs may reduce the bioavailability of <e20> drug2 </e20> .
mechanism	repeated doses of <e10> drug1 </e10> may decrease the serum concentrations of <e20> drug2 </e20> .
mechanism	barbiturates , <e10> drug1 </e10> , quinidine , or amiodarone may inhibit <e20> drug2 </e20> metabolism , resulting in decreased plasma levels and toxicity .
mechanism	digoxin : <e10> drug1 </e10> may enhance the metabolism of <e20> drug2 </e20> by increasing renal clearance .
mechanism	agents that are potent inhibitors of cyp3a4 ( such as ketoconazole , erythromycin , ritonavir , clarithromycin , drug1 , saquinavir , <e10> drug1 </e10> , saquinavir , troleandomycin ) may increase the plasma concentrations of <e20> drug2 </e20> .
mechanism	cytochrome p - 450 inducers , including <e10> drug1 </e10> , may interfere with <e20> drug2 </e20> metabolism and reduce the elimination of drug2 .
mechanism	in em individuals , <e10> drug1 </e10> decreased plasma concentrations of <e20> drug2 </e20> .
mechanism	tricyclic _ antidepressants ( amitriptyline , imipramine , <e10> drug1 </e10> , sertraline ) have been reported to decrease plasma concentrations of <e20> drug2 </e20> .
mechanism	in a placebo - controlled study , intravenous <e10> drug1 </e10> decreased the <e20> drug2 </e20> plasma levels by 31 % ( 95 % ci , - 50 % to - 12 % ) , and in a randomized trial , an increase of drug2 plasma levels by 30 % ( 95 % ci , - 22 % to 50 % ) was observed .
mechanism	theophylline : as <e10> drug1 </e10> has been reported to decrease the absorption of <e20> drug2 </e20> , the increase in the half - life of drug2 is likely to reduce the pharmacologic effect of drug2 .
mechanism	<e12> drug1 </e12> may interfere with the absorption of <e20> drug2 </e20> , resulting in a decrease in the maximum plasma concentration ( cmax ) and auc .
mechanism	<e10> drug1 </e10> may decrease the bioavailability of <e20> drug2 </e20> .
mechanism	quinolone _ antibiotic s : drug1 , drug2 , or ciprofloxacin : interaction with <e11> drug1 </e11> may increase plasma concentrations of <e20> drug2 </e20> , ketoconazole , or ciprofloxacin .
mechanism	phenytoin : <e12> drug1 </e12> may inhibit the metabolism of <e20> drug2 </e20> , resulting in a decrease in the serum concentrations of drug2 .
mechanism	drug1 : <e10> drug1 </e10> may increase the clearance of <e20> drug2 </e20> .
mechanism	pharmacokinetic studies have demonstrated that the <e10> drug1 </e10> auc and cmax are decreased by approximately 30 % and approximately 60 % , respectively , when <e20> drug2 </e20> is coadministered .
mechanism	methenamine therapy urinary excretion of <e10> drug1 </e10> is increased by renal tubular secretion of <e20> drug2 </e20> .
mechanism	drug1 : <e10> drug1 </e10> may increase the plasma concentrations of <e20> drug2 </e20> .
mechanism	drug1 : <e10> drug1 </e10> increases <e20> drug2 </e20> clearance , which may predispose patients to the metabolic syndrome .
mechanism	the administration of <e10> drug1 </e10> is a risk factor for the clearance of <e20> drug2 </e20> .
mechanism	the administration of <e10> drug1 </e10> increased the plasma concentration of <e20> drug2 </e20> by approximately one - third to one - half .
mechanism	<e10> drug1 </e10> increased the plasma concentrations of <e20> drug2 </e20> and the intracellular half - life of drug2 .
mechanism	pharmacokinetic data from in vitro studies indicate that <e10> drug1 </e10> may increase the exposure of <e20> drug2 </e20> , which has a 50 % efficacy reduction when given with the metabolite of drug1 , drug1 .
mechanism	after multiple dosing , the serum concentrations of <e10> drug1 </e10> were reduced by 43 % in patients receiving high - dose <e20> drug2 </e20> and increased by 25 % in patients receiving low - dose drug2 .
mechanism	inhibitors or substrates of cyp3a4 , including ketoconazole , drug1 , clarithromycin , <e10> drug1 </e10> , ritonavir , nelfinavir , nefazodone , saquinavir , telithromycin , troleandomycin , and troleandomycin , may significantly reduce the bioavailability of <e20> drug2 </e20> .
mechanism	these alterations in cyp3a4 activity may , in part , explain the increased plasma concentrations of <e10> drug1 </e10> after initiation of <e20> drug2 </e20> therapy .
mechanism	in vitro data suggest that <e10> drug1 </e10> may decrease the metabolism of <e20> drug2 </e20> .
mechanism	however , in the presence of <e10> drug1 </e10> , the bioavailability of <e20> drug2 </e20> decreased by approximately 50 % .
mechanism	drug1 : <e10> drug1 </e10> decreases the bioavailability of <e20> drug2 </e20> , isoniazid , phenytoin , and theophylline .
mechanism	cimetidine : in a dose - dependent study in healthy volunteers , # mg of <e10> drug1 </e10> daily for # days increased the <e20> drug2 </e20> auc from # to # . 5 times and the auc from # to # times , respectively .
mechanism	total body clearance of <e11> drug1 </e11> is impaired by <e20> drug2 </e20> and is associated with a decrease in renal clearance of drug2 .
mechanism	agents that are inhibitory to cyp3a4 ( eg , ketoconazole , itraconazole , ritonavir , nelfinavir , drug2 , <e10> drug1 </e10> , troleandomycin , drug1 _ methionine , astemizole , drug2 ) are expected to decrease the elimination of <e20> drug2 </e20> .
mechanism	in normal volunteers , coadministration of <e10> drug1 </e10> decreased plasma levels of <e20> drug2 </e20> .
mechanism	drugs which induce cyp3a4 activity ( eg , drug2 , <e10> drug1 </e10> , itraconazole , phenytoin , rifampin , clarithromycin , indinavir , saquinavir , indinavir , indinavir _ sulfate ) may increase the plasma concentration of <e20> drug2 </e20> and may require increases in drug2 dose to achieve steady state .
mechanism	multivalent cation - containing products : the concomitant administration of <e11> drug1 </e11> tablets with multivalent cation - containing products ( eg , calcium _ channel _ blockers and <e20> drug2 </e20> ) may increase the absorption of cations in these products by a factor of 5 or more .
mechanism	drugs that may increase hepatic metabolism of <e11> drug1 </e11> include : <e20> drug2 </e20> , digoxin , indinavir , itraconazole , ketoconazole , methadone , phenytoin , rifampin , quinidine , saquinavir , valproate , warfarin .
mechanism	<e12> drug1 </e12> ( phenytoin , carbamazepine , phenobarbital , felbamate ) inhibit the metabolism of <e20> drug2 </e20> by releasing the metabolite ( s ) ( drug2 ) into the bloodstream .
mechanism	co - administration of <e10> drug1 </e10> decreased the plasma levels of <e20> drug2 </e20> by 50 % on the seventh day of co - administration .
mechanism	drugs that induce hepatic metabolism of <e11> drug1 </e11> include : acetaminophen ( tylenol ) , drug2 ( <e20> drug2 </e20> ) , indomethacin ( ciprofloxacin ) , isoniazid ( ethionamide ) , itraconazole ( itraconazole ) , itraconazole sulfate , itraconazole sulfate , quinine ( quinine ) , theophylline ( theophylline ) , troleandomycin ( trileandomycin ) , and valproate ( carbamazepine ) .
mechanism	inducers and inhibitors of aminoglycoside proteases : in a study in healthy volunteers , <e10> drug1 </e10> decreased the steady - state plasma concentration of <e20> drug2 </e20> by a mean of 50 % and reduced the plasma concentration of a selective cyclosporine a inhibitor by a mean of 30 % at # mg / day .
mechanism	metoprolol - administration of <e10> drug1 </e10> # mg / day for # days reduced <e20> drug2 </e20> exposure by 36 % .
mechanism	drug1 : <e10> drug1 </e10> decreased the half - life of <e20> drug2 </e20> by a mean of 19 % compared to drug2 alone .
mechanism	<e12> drug1 </e12> may interfere with the absorption of <e20> drug2 </e20> , resulting in reduced serum concentrations .
mechanism	ethanol : clinical evidence suggests that <e10> drug1 </e10> and alcohol may decrease the absorption of <e20> drug2 </e20> , resulting in a lower serum concentration of the latter and a lower auc .
mechanism	co - medications that induce hepatic enzymes such as <e10> drug1 </e10> , carbamazepine , or cyclosporine may increase the clearance of <e20> drug2 </e20> .
mechanism	naproxen , naproxen _ sodium , and <e10> drug1 </e10> may decrease plasma levels of <e20> drug2 </e20> and thus increase the effect of drug2 .
mechanism	<e10> drug1 </e10> reduced the clearance of <e20> drug2 </e20> by about 40 % .
mechanism	multivalent cation - containing products : clinical studies , as well as postmarketing observations , have shown that multivalent cation - containing products ( such as aspirin , ketoprofen , <e10> drug1 </e10> , diclofenac , clofibrate ) have been shown to increase the absorption of <e20> drug2 </e20> , and therefore may increase the risk of drug2 - related adverse events .
mechanism	drug1 : <e10> drug1 </e10> may decrease the clearance of <e20> drug2 </e20> .
mechanism	valproate : a study of 5 healthy subjects revealed a strong reduction in serum <e10> drug1 </e10> concentrations following coadministration with <e20> drug2 </e20> .
mechanism	drugs that induce hepatic enzymes such as phenytoin , <e10> drug1 </e10> , phenobarbital , and barbiturates may decrease the clearance of <e20> drug2 </e20> .
mechanism	phenobarbital : coadministration of <e10> drug1 </e10> with <e20> drug2 </e20> , clarithromycin , rifabutin , or cimetidine resulted in increases in auc and cmax , and decreases in auc and cmin .
mechanism	in vitro , <e10> drug1 </e10> inhibited <e20> drug1 </e20> metabolism by inhibiting cyp2c9 and cyp2d6 and increasing auc values .
mechanism	<e10> drug1 </e10> decreases the clearance of <e20> drug2 </e20> .
mechanism	the following are the known drugs that can inhibit the metabolism of <e10> drug1 </e10> to induce toxicity : certain antibiotics ( e , g , , ampicillin , tetracycline , bacitracin , ciprofloxacin , <e20> drug2 </e20> , cefazolin , clarithromycin , indomethacin , itraconazole , nefazodone , nelfinavir , rifampin , saquinavir , telithromycin , troleandomycin ) , antacids , barbiturates , calcium supplements , chloramphenicol , dapsone , fluvoxamine , glucocorticoids , phenylbutazone , methadone , pentamidine , phenytoin , salicylates , tamoxifen , thiazide _ diuretics , tolbutamide , theophy
mechanism	h2 _ receptor _ antagonists : <e10> drug1 </e10> , drug2 , indomethacin , and cimetidine may increase the plasma concentrations of <e20> drug2 </e20> and indomethacin .
mechanism	mao _ inhibitors maoi _ antidepressants , tricyclic _ antidepressants ( <e10> drug1 </e10> , nortriptyline ) , and phenothiazines may increase <e20> drug2 </e20> clearance .
mechanism	blood levels of <e10> drug1 </e10> were reduced by # % when administered concomitantly with <e20> drug2 </e20> .
mechanism	an increase in the concentration of drug1 has been reported when <e10> drug1 </e10> is coadministered with cyclosporine , carbamazepine , <e20> drug2 </e20> , hexobarbital , phenytoin , alfentanil , phenobarbital , phenytoin plus cisapride , phenytoin plus disopyramide , phenobarbital plus disopyramide , disopyramide plus disopyramide , triazolam , and / or tolbutamide .
mechanism	atorvastatin : <e10> drug1 </e10> may inhibit the metabolism of <e20> drug2 </e20> and decrease its plasma levels .
mechanism	drug1 : <e10> drug1 </e10> has been reported to decrease blood levels of <e20> drug2 </e20> .
mechanism	cyclosporine , digoxin , methotrexate and aminoglycosides : <e10> drug1 </e10> may interfere with absorption of <e20> drug2 </e20> , digoxin , and aminoglycosides .
mechanism	drug1 : <e10> drug1 </e10> increases the clearance of <e20> drug2 </e20> by approximately 10 % and the volume of distribution by approximately 10 % .
mechanism	- drugs that induce hepatic enzymes such as <e10> drug1 </e10> , drug2 , amiodarone , phenobarbital , carbamazepine , and drug2 may increase <e20> drug2 </e20> plasma levels and decrease the efficacy of drug2 .
mechanism	although specific studies have not been performed , <e10> drug1 </e10> may decrease the absorption of <e20> drug2 </e20> .
mechanism	concomitant oral administration of <e10> drug1 </e10> ( 50 mg three times a day ) and <e20> drug2 </e20> ( 25 mg three times a day ) in healthy volunteers significantly decreased the clearance of drug1 by 23 % ( cmax , # ng / ml ) .
mechanism	potential for reduction in plasma concentrations of <e10> drug1 </e10> and cimetidine when coadministered with <e20> drug2 </e20> .
mechanism	<e11> drug1 </e11> , in doses of # mg / kg per day , significantly decreased the hepatic auc and cmax values of <e20> drug2 </e20> by 6 % and 17 % , respectively .
mechanism	<e10> drug1 </e10> may decrease the bioavailability of <e20> drug2 </e20> .
mechanism	methotrexate : <e10> drug1 </e10> may reduce the clearance of <e20> drug2 </e20> .
mechanism	benzodiazepines : combination <e10> drug1 </e10> and <e20> drug2 </e20> ( 5 mg , q24h ) produce a 20 % decrease in auc of drug2 and a 20 % decrease in auc of drug1 .
mechanism	<e10> drug1 </e10> also inhibits the metabolism of theophylline , <e20> drug2 </e20> , and valproate , leading to a longer elimination half - life of these three drugs .
mechanism	in eight hiv - infected patients , the plasma concentrations of <e10> drug1 </e10> were increased by 4 . 1 - fold ( median : # micrograms / ml ) after coadministration with <e20> drug2 </e20> .
mechanism	in vitro studies have shown that <e10> drug1 </e10> decreased the binding of <e20> drug2 </e20> to its primary binding sites on the renal tubular epithelium .
mechanism	although specific studies have not been conducted , it is likely that coadministration of certain antibiotics ( e , g , , ampicillin , tetracycline , clindamycin , erythromycin , <e10> drug1 </e10> , doxycycline , miconazole , nalidixic _ acid , rifampin , troleandomycin , verapamil ) with <e21> drug2 </e21> may have resulted in an increase in the bioavailability of the active ingredient .
mechanism	<e10> drug1 </e10> has been reported to decrease <e20> drug2 </e20> plasma concentrations , and thus an increase in the auc of drug2 may occur .
mechanism	drug1 : <e10> drug1 </e10> was reported to inhibit the metabolism of <e20> drug2 </e20> .
mechanism	drug1 : <e10> drug1 </e10> increased plasma <e20> drug2 </e20> concentrations ( p = 0 . 008 ) and induced a 50 % increase in drug2 exposure at the auc of drug2 ( 0 , 60 , and 120 minutes ) .
mechanism	ibuprofen - <e10> drug1 </e10> increased <e20> drug2 </e20> levels in vitro by 17 % .
mechanism	drugs that cause hepatic enzyme levels to increase by interfering with hepatic metabolism of drugs that cause hepatic enzyme levels to decrease ( eg , phenytoin , <e10> drug1 </e10> , carbamazepine ) may increase plasma <e20> drug2 </e20> concentrations and thus may require increased valproate doses to achieve the desired blood levels .
mechanism	some quinolones , including <e10> drug1 </e10> , may increase the clearance of other <e22> drug2 </e22> .
mechanism	<e10> drug1 </e10> decreased the clearance of <e20> drug2 </e20> by 25 % and decreased its renal clearance by 34 % .
mechanism	hepatic enzyme inducers , such as <e10> drug1 </e10> , may increase the plasma levels of <e20> drug2 </e20> .
mechanism	<e10> drug1 </e10> may inhibit <e20> drug2 </e20> metabolism in renal tubular epithelium .
mechanism	drug1 : <e10> drug1 </e10> increases the plasma concentrations of <e20> drug2 </e20> .
mechanism	<e10> drug1 </e10> has been shown to increase the absorption of cimetidine and <e20> drug2 </e20> .
mechanism	drug1 : <e10> drug1 </e10> may increase plasma concentrations of <e20> drug2 </e20> .
mechanism	hepatic enzyme inducers , interferon - g , and drug1 : <e10> drug1 </e10> increased the metabolism of <e20> drug2 </e20> by increasing drug2 elimination and increasing plasma concentrations of drug2 .
mechanism	these studies indicate that <e10> drug1 </e10> may have a significant effect on the metabolism of <e20> drug2 </e20> .
mechanism	drug1 : <e10> drug1 </e10> significantly reduced the plasma level of <e20> drug2 </e20> and amphetamine _ derivatives in healthy volunteers and in patients with parkinson disease .
mechanism	although specific studies have not been performed , data suggest that co - administration of <e10> drug1 </e10> with the following drugs may decrease drug1 pharmacokinetics : ampicillin / tazobactam , ciprofloxacin , ciprofloxacin , erythromycin , carbamazepine , cyclosporine , disulfiram , fluoxetine , pimozide , quinidine , <e20> drug2 </e20> .
mechanism	drug1 : <e10> drug1 </e10> increased the serum concentration of <e20> drug2 </e20> and decreased the plasma levels of cilostazol .
mechanism	theophylline <e11> drug1 </e11> increased <e20> drug2 </e20> by 39 % and decreased calcium absorption by 36 % .
mechanism	however , the systemic absorption of <e10> drug1 </e10> is increased by several - fold when administered with <e20> drug2 </e20> , suggesting a possible mechanism for drug2 toxicity .
mechanism	methotrexate : ketoprofen , <e10> drug1 </e10> , indomethacin , and sodium _ valproate may decrease the bioavailability of <e20> drug2 </e20> .
mechanism	antacids containing <e10> drug1 </e10> ( ≤ mcem ) , zinc ( ≤ zn ) , iron ( ≤ fe ) , calcium ( ≤ ca ) , or aluminum ( ≤ al ) may interfere with absorption of <e20> drug2 </e20> and increase the plasma concentrations of drug2 .
mechanism	ibuprofen - <e10> drug1 </e10> significantly decreased plasma concentrations of <e20> drug2 </e20> .
mechanism	ritonavir : coadministration of <e10> drug1 </e10> # hours prior to dosing with <e20> drug2 </e20> resulted in a 40 % increase in drug1 exposure .
mechanism	in vitro data suggest that <e10> drug1 </e10> may increase the clearance of some drugs , such as <e20> drug2 </e20> and rifampin .
mechanism	however , in another study , <e10> drug1 </e10> at a dose of # mg / kg / day for # days resulted in a 30 % increase in the plasma levels of the <e20> drug2 </e20> concomitantly with an approximately 6 - fold increase in the plasma concentrations of the drug2 hydrochloride metabolite .
mechanism	metoprolol - administration of <e10> drug1 </e10> may reduce the plasma concentration of <e20> drug2 </e20> .
mechanism	products containing calcium or aluminum containing <e10> drug1 </e10> ( 10 mg or more / kg ) have been reported to decrease the plasma concentrations of <e20> drug2 </e20> , resulting in increased blood levels .
mechanism	<e12> drug1 </e12> may interfere with the absorption of <e20> drug2 </e20> , resulting in elevated serum levels and auc values .
mechanism	substances that are potent inhibitors of cyp2c9 ( e , g , , ketoconazole , itraconazole , ritonavir , drug1 , clarithromycin , <e10> drug1 </e10> , indinavir , nelfinavir ) may increase the clearance of <e20> drug2 </e20> .
mechanism	however , other published studies have shown that <e10> drug1 </e10> decreased plasma <e20> drug2 </e20> levels by approximately 6 % .
mechanism	plasma levels of <e10> drug1 </e10> have been reported to be decreased by <e20> drug2 </e20> , almotriptan , and cimetidine , and the drug1 metabolite macrotoxin has been reported to decrease the metabolism of drug1 .
mechanism	ketoconazole : coadministration of <e10> drug1 </e10> and <e20> drug2 </e20> for # days caused a 20 % reduction in drug2 auc , as did coadministration of drug2 and a prothrombin time - resolved dye .
mechanism	antifungals : in vitro data indicate that <e10> drug1 </e10> and drug1 _ derivatives may inhibit the metabolism of <e20> drug2 </e20> and enteroconazole by inhibiting cyp3a4 .
mechanism	some <e12> drug1 </e12> have been reported to inhibit <e20> drug2 </e20> metabolism by altering the activity of its cofactor , the cytochrome p450 3a4 enzyme .
mechanism	and <e11> drug1 </e11> may reduce the bioavailability of <e20> drug2 </e20> and carbamazepine .
mechanism	<e10> drug1 </e10> ( 10 mg qid ) decreased the auc of <e20> drug2 </e20> by 50 % and the cmax by 30 % .
mechanism	<e10> drug1 </e10> has been reported to increase the clearance of oral <e20> drug2 </e20> and the elimination half - life of ketoconazole by approximately 50 % .
mechanism	oral <e10> drug1 </e10> may decrease the clearance of <e20> drug2 </e20> and its progesterone equivalent in postmenopausal women .
mechanism	in vitro studies have shown that <e10> drug1 </e10> increases the metabolism of <e20> drug2 </e20> .
mechanism	rifabutin : coadministration of <e10> drug1 </e10> with <e20> drug2 </e20> resulted in a 13 % increase in drug1 auc and a 39 % decrease in cmax .
mechanism	in addition , higher - than - recommended dose <e10> drug1 </e10> has been reported to reduce the plasma levels of <e20> drug2 </e20> by approximately 20 % .
mechanism	inducers and inhibitors of the cyp3a4 ( such as <e10> drug1 </e10> and itraconazole ) inhibit the metabolism of <e20> drug2 </e20> .
mechanism	a study in a rat model showed that <e10> drug1 </e10> # mg / kg for # days decreased the levels of <e20> drug2 </e20> in plasma , decreased the metabolism of drug2 , and increased the half - life of drug2 by 40 % to 50 % .
mechanism	antacids : in a study of oral antacids containing various drug1 , calcium , and aluminum contents , <e10> drug1 </e10> ( 0 . 058 mg / ml ) increased the <e20> drug2 </e20> effective dose by 17 % .
mechanism	in addition to this observed interaction , <e10> drug1 </e10> increased the levels of <e20> drug2 </e20> and decreased the plasma levels of cimetidine in normal subjects .
